<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Magnetic resonance perfusion for differentiating low‐grade from high‐grade gliomas at first presentation - Abrigo, JM - 2018 | Cochrane Library</title> <meta content="Magnetic resonance perfusion for differentiating low‐grade from high‐grade gliomas at first presentation - Abrigo, JM - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011551.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Magnetic resonance perfusion for differentiating low‐grade from high‐grade gliomas at first presentation - Abrigo, JM - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011551.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011551.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Magnetic resonance perfusion for differentiating low‐grade from high‐grade gliomas at first presentation" name="citation_title"/> <meta content="Jill M Abrigo" name="citation_author"/> <meta content="The Chinese University of Hong Kong" name="citation_author_institution"/> <meta content="jillabrigo@cuhk.edu.hk" name="citation_author_email"/> <meta content="Daniel M Fountain" name="citation_author"/> <meta content="Addenbrookes Hospital" name="citation_author_institution"/> <meta content="James M Provenzale" name="citation_author"/> <meta content="Duke University Medical Center" name="citation_author_institution"/> <meta content="Eric K Law" name="citation_author"/> <meta content="The Chinese University of Hong Kong" name="citation_author_institution"/> <meta content="Joey SW Kwong" name="citation_author"/> <meta content="Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong" name="citation_author_institution"/> <meta content="Michael G Hart" name="citation_author"/> <meta content="Addenbrookes Hospital" name="citation_author_institution"/> <meta content="Wilson Wai San Tam" name="citation_author"/> <meta content="National University of Singapore, National University Health System" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD011551.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011551.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011551.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011551.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Magnetic Resonance Imaging; Astrocytoma [diagnostic imaging]; Brain Neoplasms [*diagnostic imaging]; Cross‐Sectional Studies; Glioma [*diagnostic imaging]; Oligodendroglioma [diagnostic imaging]; Sensitivity and Specificity" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011551.pub2&amp;doi=10.1002/14651858.CD011551.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011551\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011551\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011551.pub2",title:"Magnetic resonance perfusion for differentiating low\\u2010grade from high\\u2010grade gliomas at first presentation",firstPublishedDate:"Jan 22, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011551.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011551.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011551.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011551.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011551.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011551.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011551.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011551.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011551.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011551.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3566 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011551.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-sec-0067"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-sec-0063"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/appendices#CD011551-sec-0072"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/table_n/CD011551StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/table_n/CD011551StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Magnetic resonance perfusion for differentiating low‐grade from high‐grade gliomas at first presentation </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#CD011551-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jill M Abrigo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#CD011551-cr-0003">Daniel M Fountain</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#CD011551-cr-0004">James M Provenzale</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#CD011551-cr-0005">Eric K Law</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#CD011551-cr-0006">Joey SW Kwong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#CD011551-cr-0007">Michael G Hart</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information#CD011551-cr-0008">Wilson Wai San Tam</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information/en#CD011551-sec-0079">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011551.pub2">https://doi.org/10.1002/14651858.CD011551.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011551-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011551-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011551-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011551-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011551-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011551-abs-0001" lang="en"> <section id="CD011551-sec-0001"> <h3 class="title" id="CD011551-sec-0001">Background</h3> <p>Gliomas are the most common primary brain tumour. They are graded using the WHO classification system, with Grade II‐IV astrocytomas, oligodendrogliomas and oligoastrocytomas. Low‐grade gliomas (LGGs) are WHO Grade II infiltrative brain tumours that typically appear solid and non‐enhancing on magnetic resonance imaging (MRI) scans. People with LGG often have little or no neurologic deficit, so may opt for a watch‐and‐wait‐approach over surgical resection, radiotherapy or both, as surgery can result in early neurologic disability. Occasionally, high‐grade gliomas (HGGs, WHO Grade III and IV) may have the same MRI appearance as LGGs. Taking a watch‐and‐wait approach could be detrimental for the patient if the tumour progresses quickly. Advanced imaging techniques are increasingly used in clinical practice to predict the grade of the tumour and to aid clinical decision of when to intervene surgically. One such advanced imaging technique is magnetic resonance (MR) perfusion, which detects abnormal haemodynamic changes related to increased angiogenesis and vascular permeability, or "leakiness" that occur with aggressive tumour histology. These are reflected by changes in cerebral blood volume (CBV) expressed as rCBV (ratio of tumoural CBV to normal appearing white matter CBV) and permeability, measured by <i>K</i><sup>trans</sup>. </p> </section> <section id="CD011551-sec-0002"> <h3 class="title" id="CD011551-sec-0002">Objectives</h3> <p>To determine the diagnostic test accuracy of MR perfusion for identifying patients with primary solid and non‐enhancing LGGs (WHO Grade II) at first presentation in children and adults. In performing the quantitative analysis for this review, patients with LGGs were considered disease positive while patients with HGGs were considered disease negative. </p> <p>To determine what clinical features and methodological features affect the accuracy of MR perfusion. </p> </section> <section id="CD011551-sec-0003"> <h3 class="title" id="CD011551-sec-0003">Search methods</h3> <p>Our search strategy used two concepts: (1) glioma and the various histologies of interest, and (2) MR perfusion. We used structured search strategies appropriate for each database searched, which included: MEDLINE (Ovid SP), Embase (Ovid SP), and Web of Science Core Collection (Science Citation Index Expanded and Conference Proceedings Citation Index). The most recent search for this review was run on 9 November 2016. </p> <p>We also identified 'grey literature' from online records of conference proceedings from the American College of Radiology, European Society of Radiology, American Society of Neuroradiology and European Society of Neuroradiology in the last 20 years. </p> </section> <section id="CD011551-sec-0004"> <h3 class="title" id="CD011551-sec-0004">Selection criteria</h3> <p>The titles and abstracts from the search results were screened to obtain full‐text articles for inclusion or exclusion. We contacted authors to clarify or obtain missing/unpublished data. </p> <p>We included cross‐sectional studies that performed dynamic susceptibility (DSC) or dynamic contrast‐enhanced (DCE) MR perfusion or both of untreated LGGs and HGGs, and where rCBV and/or <i>K</i><sup>trans</sup> values were reported. We selected participants with solid and non‐enhancing gliomas who underwent MR perfusion within two months prior to histological confirmation. We excluded studies on participants who received radiation or chemotherapy before MR perfusion, or those without histologic confirmation. </p> </section> <section id="CD011551-sec-0005"> <h3 class="title" id="CD011551-sec-0005">Data collection and analysis</h3> <p>Two review authors extracted information on study characteristics and data, and assessed the methodological quality using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) tool. We present a summary of the study characteristics and QUADAS‐2 results, and rate studies as good quality when they have low risk of bias in the domains of reference standard of tissue diagnosis and flow and timing between MR perfusion and tissue diagnosis. </p> <p>In the quantitative analysis, LGGs were considered disease positive, while HGGs were disease negative. The sensitivity refers to the proportion of LGGs detected by MR perfusion, and specificity as the proportion of detected HGGs. We constructed two‐by‐two tables with true positives and false negatives as the number of correctly and incorrectly diagnosed LGG, respectively, while true negatives and false positives are the number of correctly and incorrectly diagnosed HGG, respectively. </p> <p>Meta‐analysis was performed on studies with two‐by‐two tables, with further sensitivity analysis using good quality studies. Limited data precluded regression analysis to explore heterogeneity but subgroup analysis was performed on tumour histology groups. </p> </section> <section id="CD011551-sec-0006"> <h3 class="title" id="CD011551-sec-0006">Main results</h3> <p>Seven studies with small sample sizes (4 to 48) met our inclusion criteria. These were mostly conducted in university hospitals and mostly recruited adult patients. All studies performed DSC MR perfusion and described heterogeneous acquisition and post‐processing methods. Only one study performed DCE MR perfusion, precluding quantitative analysis. </p> <p>Using patient‐level data allowed selection of individual participants relevant to the review, with generally low risks of bias for the participant selection, reference standard and flow and timing domains. Most studies did not use a pre‐specified threshold, which was considered a significant source of bias, however this did not affect quantitative analysis as we adopted a common rCBV threshold of 1.75 for the review. Concerns regarding applicability were low. </p> <p>From published and unpublished data, 115 participants were selected and included in the meta‐analysis. Average rCBV (range) of 83 LGGs and 32 HGGs were 1.29 (0.01 to 5.10) and 1.89 (0.30 to 6.51), respectively. Using the widely accepted rCBV threshold of &lt;1.75 to differentiate LGG from HGG, the summary sensitivity/specificity estimates were 0.83 (95% CI 0.66 to 0.93)/0.48 (95% CI 0.09 to 0.90). Sensitivity analysis using five good quality studies yielded sensitivity/specificity of 0.80 (95% CI 0.61 to 0.91)/0.67 (95% CI 0.07 to 0.98). Subgroup analysis for tumour histology showed sensitivity/specificity of 0.92 (95% CI 0.55 to 0.99)/0.42 (95% CI 0.02 to 0.95) in astrocytomas (6 studies, 55 participants) and 0.77 (95% CI 0.46 to 0.93)/0.53 (95% CI 0.14 to 0.88) in oligodendrogliomas+oligoastrocytomas (6 studies, 56 participants). Data were too sparse to investigate any differences across subgroups. </p> </section> <section id="CD011551-sec-0007"> <h3 class="title" id="CD011551-sec-0007">Authors' conclusions</h3> <p>The limited available evidence precludes reliable estimation of the performance of DSC MR perfusion‐derived rCBV for the identification of grade in untreated solid and non‐enhancing LGG from that of HGG. Pooled data yielded a wide range of estimates for both sensitivity (range 66% to 93% for detection of LGGs) and specificity (range 9% to 90% for detection of HGGs). Other clinical and methodological features affecting accuracy of the technique could not be determined from the limited data. A larger sample size of both LGG and HGG, preferably using a standardised scanning approach and with an updated reference standard incorporating molecular profiles, is required for a definite conclusion. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011551-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011551-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011551-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011551-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011551-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011551-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011551-abs-0003" lang="en"> <h3>How accurate is MR perfusion, an advanced MRI method, for differentiating low‐grade gliomas from high‐grade gliomas in children and adults? </h3> <p><b>Why is differentiation of low‐grade and high‐grade gliomas important?</b> </p> <p>Low‐grade gliomas (LGGs) are slow growing brain tumours that have a typical appearance on standard MRI. Patients with LGGs who have few or no symptoms may prefer to delay treatment until such time they experience progression of their symptoms or appearance of the tumour on MRI; this is called the watch‐and‐wait approach. However occasionally, high‐grade gliomas (HGGs), which are aggressive and require early treatment, can mimic the appearance of LGGs. It is only by examining tissues obtained by surgery ‐ either through sampling (biopsy) or removal of tumour (resection) ‐ can LGG and HGG be definitively differentiated. But a patient with few or no symptoms may want to avoid risking early neurologic disability resulting from surgery. Thus an accurate noninvasive method to differentiate gliomas can aid patients' decision making whether to opt for a watch‐and‐wait approach or undergo early treatment. </p> <p><b>What is the aim of this review?</b> </p> <p>The review aims to determine how accurate MR perfusion is for differentiating LGGs and HGGs, and what factors affect its accuracy. Researchers in Cochrane included seven studies to answer this question. </p> <p><b>What was studied in this review?</b> </p> <p>An advanced MRI technique called MR perfusion was studied. This method detects abnormal blood vessels which are increased from low‐ to high‐grade gliomas. Unlike surgery, MR perfusion is noninvasive and allows clinicians to determine if a watch‐and‐wait approach can be adopted by patients, i.e. delay treatment including the initial tissue examination which requires surgery. </p> <p><b>What are the main results of the review?</b> </p> <p>The analysis included results from 115 patients. The results indicate that in theory, if MR perfusion were to be used in 100 patients with brain tumours that look like LGG on standard MRI scan, of whom 72 actually have LGG, then:<br/> ‐ an estimated 74 will have an MR perfusion result indicating that they have LGGs, and of these 15 will have HGGs;<br/> ‐ an estimated 26 will have an MR perfusion result indicating that they have HGGs, and of these 13 will have LGGs. </p> <p><b>How reliable are the results of the studies in this review?</b> </p> <p>In the included studies, the diagnosis of LGG or HGG was made by assessing all patients with tissue examination, and a majority underwent resection. This is considered a reliable method for deciding whether patients actually had LGGs or HGGs. </p> <p>The small number of patients that were included in this review is a major limitation to the analysis. Estimates from individual studies and pooled data were variable and/or had a wide range. The numbers reported in the main results above are an average across studies in the review, but it is unknown if MR perfusion will always produce these results. Further, the included studies differed in how MR perfusion was performed, and pooling of data for the analysis may be inappropriate. </p> <p><b>Who do the results of this review apply to?</b> </p> <p>The included studies were carried out in Europe (Italy, Sweden, Spain, France), Asia (Japan) and South America (Brazil) and MR perfusion was mostly performed in university hospitals. Most studies recruited adults so the results may not be representative of children. </p> <p><b>What are the implications of this review?</b> </p> <p>Our results based on 115 patients showed that MR perfusion may detect 66% to 93% of LGGs, which means that 7% to 34% of people with LGGs may be misclassified as having HGGs and thus may undergo early invasive treatment with an accompanying risk of adverse events. Meanwhile, around half of people with HGGs may be misclassified as having LGGs, and thus may suffer from delayed treatment. Due to uncertainty in the estimates this may range from 9% to 90% of patients. Given the wide range of estimates, currently, it cannot be determined how accurate MR perfusion is for differentiating LGGs and HGGs. Future studies to inform evidence would need to include larger numbers of patients with LGG and HGG. </p> <p><b>How up to date is this review?</b> </p> <p>We searched for and used studies published from 1990 to November 2016.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011551-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011551-sec-0067"></div> <h3 class="title" id="CD011551-sec-0068">Implications for practice</h3> <section id="CD011551-sec-0068"> <p>Currently, the limited available evidence neither supports nor refutes the use of MR perfusion for the differentiation of primary and untreated solid and non‐enhancing LGGs and HGGs. </p> </section> <h3 class="title" id="CD011551-sec-0069">Implications for research</h3> <section id="CD011551-sec-0069"> <p>There is limited evidence available in the literature and even fewer good quality studies reporting the diagnostic accuracy of MR perfusion for grading solid and non‐enhancing astrocytic and oligodendrogial gliomas. More research and larger sample sizes are required, but standardisation of the technique is equally important as variations in MRI acquisition and post‐processing are known to affect perfusion values. Current practice recommendations (<a href="./references#CD011551-bbs2-0036" title="EssigM , ShiroishiMS , NguyenTB , SaakeM , ProvenzaleJM , EnterlineD , et al. Perfusion MRI: the five most frequently asked technical questions. AJR. American Journal of Roentgenology2013;200(1):24–34. [DOI: 10.2214/AJR.12.9543] ">Essig 2013</a>; <a href="./references#CD011551-bbs2-0066" title="WelkerK , BoxermanJ , KalninA , KaufmannT , ShiroishiM , WintermarkM , American Society of Functional Neuroradiology MR Perfusion Standards and Practice Subcommittee of the ASFNR Clinical Practice Committee. ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain. AJNR. American Journal of Neuroradiology2015;36(6):E41‐51. [DOI: 10.3174/ajnr.A4341] ">Welker 2015</a>) can pave the way for a harmonised approach and should be considered by future studies. Such efforts will facilitate handling of multicentre perfusion data and allow better assessment of the clinical applicability of the technique. </p> <p>However, the recent nosological shift in the WHO classification of brain tumours (<a href="./references#CD011551-bbs2-0044" title="LouisDN , PerryA , ReifenbergerG , vonDeimlingA , Figarella‐BrangerD , CaveneeWK , et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica2016;131(6):803‐20. [DOI: 10.1007/s00401‐016‐1545‐1] ">Louis 2016</a>) also poses a foreseeable change in the reference standard that MR perfusion will be compared against in future testing of its accuracy. In this vein, the new integrated genotype‐phenotype classification of diffuse gliomas may be more concordant with multimodal imaging rather than MR perfusion alone. Meanwhile, the clinical management of LGGs is also evolving and the watch‐and‐wait approach may become obsolete in the future (<a href="./references#CD011551-bbs2-0026" title="BoissonneauS , DuffauH . Identifying clinical risk in low grade gliomas and appropriate treatment strategies, with special emphasis on the role of surgery. Expert Review of Anticancer Therapy2017;17(7):703‐16. [DOI: 10.1080/14737140.2017.1342537] ">Boissonneau 2017</a>); recent evidence in parallel population‐based cohorts suggests clear survival benefit with early surgical resection in unselected patients with LGGs (<a href="./references#CD011551-bbs2-0040" title="JakolaAS , SkjulsvikAJ , MyrmelKS , SjåvikK , UnsgårdG , TorpSH , et al. Surgical resection versus watchful waiting in low‐grade gliomas. Annals of Oncology 2017 Aug 1;28(8):1942‐8. [DOI: 10.1093/annonc/mdx230] ">Jakola 2017</a>). In the future the relevance of MR perfusion identifying primary LGG's may diminish and its role may become limited to characterisation of tumour biologic activity, prognostication, and/or surveillance during the post‐treatment period. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011551-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011551-sec-0022"></div> <div class="table" id="CD011551-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Summary of findings table</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Almost all adults</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Setting</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Mostly university hospitals, employing exclusively 1.5T or 3T MRI scanners</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index test</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Dynamic susceptibility contrast MR perfusion (commonly gradient echo rather than spin echo sequence acquisition), usually without contrast preload, typically using arterial input function or gamma variate function post‐processing algorithms, and preferentially using region‐of‐interest method to obtain Max rCBV values (CBV ratio of tumour: contralateral normal appearing white matter) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Importance</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>For solid and non‐enhancing brain tumours with low rCBV, patients with no or little neurologic deficit may opt for conservative management over surgery to avoid early neurologic disability. Meanwhile, patients with high rCBV could favour early treatment for better tumour control. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reference standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>All with histologic examinations, majority with resection.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Mostly prospective cross sectional studies (no case‐control studies)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positive Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary accuracy<br/> (95% CI) using bivariate model </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No. of study participants / selected patients<br/> (No. of studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Implications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of studies<br/> (Based on QUADAS‐2 applied on study design and selected patients) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comments</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCBV threshold &lt;1.75 indicates LGG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity</p> <p>(proportion of LGG detected by MR perfusion)</p> <p>0.83</p> <p>(0.66, 0.93)<br/> <br/> Specificity </p> <p>(proportion of HGG detected by MR perfusion)</p> <p>0.48</p> <p>(0.09 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392 patients /</p> <p>115 with solid non‐enhancing Grade II‐IV gliomas who underwent tissue sampling within 2 months of MR perfusion </p> <p>(7 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In a hypothetical population of solid and non‐enhancing Grade II‐IV gliomas, the prevalence of LGGs and HGGs is 72% and 28%, respectively. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Given 100 patients with solid and non‐enhancing infiltrative gliomas, 72 will have LGG and 28 with HGG. </p> <p>Of 72 patients with LGG, it is expected 12 patients will be misclassified to have HGG (but this could potentially be between 5 to 24 patients) and may undergo surgery, thus risking early neurologic deterioration. Meanwhile, of 28 patients with HGG, 15 will be misclassified to have LGG (but this could be between 3 to 25 patients), which may lead to a delay in treatment that can potentially adversely affect outcomes. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generally low risk of bias in the patient selection domain, excepting 2 out of 7 studies with unclear patient sampling and inappropriate exclusion of small tumours. </p> <p>High risk of bias in the index test domain, mainly because 6 out of 7 studies did not use a pre‐specified threshold. However this did not affect meta‐analysis as we used a common rCBV threshold of 1.75.<br/> Generally low risk of bias in the reference standard domain, excepting 2 out of 7 studies with unclear method of histologic confirmation and/or presence of blinding.<br/> Low risk of bias in the flow and timing domain. </p> <p>Low concerns of applicability for the patient selection, index test and reference standard domains by using patient‐level data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low numbers (4 to 48) with target and alternative conditions per study and only 2 studies had &gt;20 patients. </p> <p>In general, individual studies had heterogeneous sensitivity and specificity, both with wide confidence intervals. </p> <p>Only 1 study had low risk of bias and low concern of applicability across all domains.</p> <p>Five studies were considered good quality (i.e., with low risk of bias in the domains of reference standard and flow &amp; timing). Their sensitivity analysis yielded sensitivity 0.80 (95% CI 0.61 to 0.91) and specificity 0.67 (95% CI 0.07 to 0.98). </p> <p>Subgroup analysis showed sensitivity/specificity of [0.92 (95% CI 0.55 to 0.99)/ 0.42 (95% CI 0.02 to 0.95) in astrocytomas and 0.77 (95% CI 0.46 to 0.93)/0.53 (95% CI 0.14 to 0.88) in oligodendrogliomas + oligoastrocytomas. </p> <p>Data were too sparse to investigate any differences across subgroups.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>HGG:</b> high‐grade glioma, <b>LGG:</b> low‐grade glioma, <b>rCBV:</b> relative cerebral blood volume </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011551-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011551-sec-0023"></div> <section id="CD011551-sec-0024"> <h3 class="title" id="CD011551-sec-0024">Target condition being diagnosed</h3> <section id="CD011551-sec-0025"> <h4 class="title">Epidemiology and pathology</h4> <p>Gliomas are tumours that arise from glial cells which form the supporting architecture of the brain. In the USA, around 18,000 gliomas are diagnosed each year, giving an incidence rate of 6.6 per 100,000. Over 90% of gliomas occur in adults (<a href="./references#CD011551-bbs2-0034" title="DolecekTA , ProppJM , StroupNE , KruchkoC . CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005‐2009. Neuro‐oncology2012;14(Suppl 5):v1‐v49. [DOI: 10.1093/neuonc/nos218] ">Dolecek 2012</a>). The incidence rate is less in Europe (<a href="./references#CD011551-bbs2-0031" title="CrocettiE , TramaA , StillerC , CaldarellaA , SoffiettiR , JaalJ , et al. Epidemiology of glial and non‐glial brain tumours in Europe. European Journal of Cancer2012;48:1532‐42. [DOI: 10.1016/j.ejca.2011.12.013] ">Crocetti 2012</a>) and lesser still in Asia and Africa, although the rate is similar when comparing developed or industrialised countries (<a href="./references#CD011551-bbs2-0049" title="OhgakiN , KleihuesP . Epidemiology and etiology of gliomas. Acta Neuropathologica2005;109:93‐108. [DOI: 10.1007/s00401‐005‐0991‐y] ">Ohgaki 2005</a>). This variation may result from underestimate of case ascertainment rather than a different genetic predisposition (<a href="./references#CD011551-bbs2-0031" title="CrocettiE , TramaA , StillerC , CaldarellaA , SoffiettiR , JaalJ , et al. Epidemiology of glial and non‐glial brain tumours in Europe. European Journal of Cancer2012;48:1532‐42. [DOI: 10.1016/j.ejca.2011.12.013] ">Crocetti 2012</a>; <a href="./references#CD011551-bbs2-0049" title="OhgakiN , KleihuesP . Epidemiology and etiology of gliomas. Acta Neuropathologica2005;109:93‐108. [DOI: 10.1007/s00401‐005‐0991‐y] ">Ohgaki 2005</a>). </p> <p>Using the World Health Organization (WHO) classification of brain tumours, gliomas are graded I‐IV to reflect increasing growth rate based on histology (<a href="./references#CD011551-bbs2-0043" title="LousDN , OhgakiH , WiestlerOD , CaveneeWK , BurgerPC , JouvetA , et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica2007;114:97‐109. [DOI: 10.1007/s00401‐007‐0243‐4] ">Louis 2007</a>). The recent 2016 WHO classification includes molecular information in addition (<a href="./references#CD011551-bbs2-0044" title="LouisDN , PerryA , ReifenbergerG , vonDeimlingA , Figarella‐BrangerD , CaveneeWK , et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica2016;131(6):803‐20. [DOI: 10.1007/s00401‐016‐1545‐1] ">Louis 2016</a>). Grade II gliomas (commonly known as 'low‐grade gliomas' (LGGs)) predominantly comprise astrocytomas, oligodendrogliomas and mixed oligoastrocytomas. LGGs tend to be diffuse and infiltrative tumours with a growth rate between that of grade I and grade III tumours. Despite growing slowly initially, they usually transform to high‐grade gliomas (HGGs) with time. The timing of this transition is highly variable and difficult to predict for an individual (<a href="./references#CD011551-bbs2-0059" title="ReesJH . Low‐grade gliomas in adults. Current Opinion in Neurology2002;15(6):657‐61. [DOI: 10.1097/01.wco.0000044760.39452.71] ">Rees 2002</a>). Approximately 50% of people with LGGs will experience malignant transformation usually within five years (<a href="./references#CD011551-bbs2-0020" title="AfraD , OsztieE , SiposL , VitanovicsD . Preoperative history and postoperative survival of supratentorial low‐grade astrocytomas. British Journal of Neurosurgery1999;13(3):299‐305. [PUBMED: 10562842] ">Afra 1999</a>; <a href="./references#CD011551-bbs2-0053" title="PiepmeierJ , ChristopherS , SpencerD , ByrneT , KimJ , KniselJP , et al. Variations in the natural history and survival of patients with supratentorial low‐grade astrocytomas. Neurosurgery1996;38(5):872‐8. [PUBMED: 8727811] ">Piepmeier 1996</a>), although more protracted growths of up to 20 years have been described (<a href="./references#CD011551-bbs2-0029" title="ClausEB , BlackPM . Survival rates and patterns of care for patients diagnosed with supratentorial low‐grade gliomas: data from the SEER program, 1973–2001. Cancer2006;106:1358‐63. [DOI: 10.1002/cncr.21733] ">Claus 2006</a>; <a href="./references#CD011551-bbs2-0058" title="RechtLD , LewR , SmithTW . Suspected low‐grade glioma: is deferring treatment safe?. Annals of Neurology1992;31(4):431‐6. [DOI: 10.1002/ana.410310413] ">Recht 1992</a>). Once transformation occurs, the tumours are highly resistant to therapy. Prognostic factors for survival include age, presence of seizures alone, histology, and larger tumour size (<a href="./references#CD011551-bbs2-0048" title="NicolatoA , GerosaMA , FinaP , IuzzolinoP , GiorguittiF , BricoloA . Prognostic factors in low‐grade supratentorial astrocytomas: a uni‐multivariate statistical analysis in 76 surgically treated adult patients. Surgical Neurology1995;44:208‐23. [PUBMED: 8545771] ">Nicolato 1995</a>; <a href="./references#CD011551-bbs2-0055" title="PignattiF , van denBentM , CurranD , DebruyneC , SylvesterR , TherasseP , et al. Prognostic factors for survival in adult patients with cerebral low grade glioma. Journal of Clinical Oncology2002;20(8):2076‐84. [DOI: 10.1200/JCO.2002.08.121] ">Pignatti 2002</a>). </p> </section> <section id="CD011551-sec-0026"> <h4 class="title">Clinical features and investigations</h4> <p>People with LGGs usually present with seizures, headaches or focal neurological features (for example, weakness). A classical presentation is a focal seizure in an otherwise healthy young adult. Other people may present with a LGG as an incidental finding after investigation for another condition (e.g. dizziness or blackouts) or after screening for employment purposes and be essentially asymptomatic. Regardless of presentation, the first‐line investigation is a contrast‐enhanced magnetic resonance imaging (MRI) scan. LGGs are solid tumours located within the brain itself and often have a characteristic appearance of poorly defined margins and little mass effect despite often large tumour volumes. Certain features strongly suggest a higher grade tumour, including contrast enhancement, signs of mass effect and significant peri‐tumoural vasogenic oedema. If any of these features is present, people often undergo early surgery (either biopsy or resection), followed by definitive oncological treatment (if appropriate). </p> </section> <section id="CD011551-sec-0027"> <h4 class="title">Management</h4> <p>If a tumour appears to be an LGG (based on a contrast‐enhanced MRI scan), optimal management is debated (<a href="./references#CD011551-bbs2-0069" title="WhittleIR . The dilemma of low grade glioma. Journal of Neurology, Neurosurgery and Psychiatry2004;75:31‐6. [DOI: 10.1136/jnnp.2004.040501] ">Whittle 2004</a>) and varies between treating centres (<a href="./references#CD011551-bbs2-0039" title="JakolaAS , MyrmelKS , KlosterR , TorpSH , LindalS , UnsgardG , et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low‐grade gliomas. JAMA2012;308(18):1881‐8. [DOI: 10.1001/jama.2012.12807] ">Jakola 2012</a>; <a href="./references#CD011551-bbs2-0064" title="SoffiettiR , BaumertBG , BelloL , vonDeimlingA , DuffauH , FrénayM , et al. Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force. European Journal of Neurology2010;17:1124‐33. [DOI: 10.1111/j.1468‐1331.2010.03151.x] ">Soffietti 2010</a>; <a href="./references#CD011551-bbs2-0065" title="van denBentMJ , AfraD , deWitteO , Ben HasselM , SchraubS , Hoang‐XuanK , et al. Long‐term efficacy of early versus delayed radiotherapy for low‐grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet2005;366(9490):985‐90. [DOI: 10.1016/S0140‐6736(05)67070‐5] ">van den Bent 2005</a>). Certain authorities would often recommend early surgical resection (<a href="./references#CD011551-bbs2-0034" title="DolecekTA , ProppJM , StroupNE , KruchkoC . CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005‐2009. Neuro‐oncology2012;14(Suppl 5):v1‐v49. [DOI: 10.1093/neuonc/nos218] ">Dolecek 2012</a>). Case series of people undergoing surgical resection for LGG, often utilising advanced neurosurgical techniques such as awake craniotomy and brain mapping (<a href="./references#CD011551-bbs2-0024" title="BelloL , FavaE , CarrabbaG , PapagnoC , GainiSM . Present day's standards in microsurgery in low‐grade gliomas. Advances and Technical Standards in Neurosurgery. Vol. 35, Springer Vienna, 2010:113‐57. [DOI: 10.1007/978‐3‐211‐99481‐8_5] ">Bello 2010</a>), have demonstrated impressive outcomes (<a href="./references#CD011551-bbs2-0035" title="DuffauH , LopesM , ArthuisF , BitarA , SichezJP , VanEffenterreR , et al. Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985‐96) and with (1996‐2003) functional mapping in the same institution. Journal of Neurology, Neurosurgery &amp; Psychiatry2005;76(6):845‐51. [DOI: 10.1136/jnnp.2004.048520] ">Duffau 2005</a>). However, studies are limited by selection bias and other methodological issues. Other management options might be conservative management or observation in selected patients. This is often known as 'watch‐and‐wait' (<a href="./references#CD011551-bbs2-0047" title="National Comprehensive Cancer Network. Central Nervous System Cancers (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns.pdfAccessed July 2017. ">NCCN Guidelines 2016</a>). In particular, when people have no or few symptoms, have deep and inaccessible tumours located in/near 'eloquent' regions of the brain, or have significant co‐morbidity which can complicate the peri‐operative setting, conservative management becomes attractive because it decreases the risk of developing neurologic deficits from surgery (<a href="./references#CD011551-bbs2-0060" title="ReijneveldJC , SitskoornMM , KleinM , NuyenJ , TaphoornMJ . Cognitive status and quality of life in patients with suspected versus proven low‐grade gliomas. Neurology2001;56(5):618‐23. [PUBMED: 11245713] ">Reijneveld 2001</a>). </p> <p>Determining optimal management is complicated by tumours that appear to be LGGs on contrast‐enhanced MRI scans but turn out to be higher grade tumours (or non‐glial tumours) when subsequently biopsied. The accuracy of a standard contrast‐enhanced MRI scan in distinguishing a grade II from a grade III astrocytoma is only approximately 30% to 50% because morphologic features of LGGs and HGGs may overlap (<a href="./references#CD011551-bbs2-0037" title="HeissWD , RaabP , LanfermannH . Multimodality assessment of brain tumors and tumor recurrence. Journal of Nuclear Medicine2011;52(10):1585‐600. [DOI: 10.2967/jnumed.110.084210] ">Heiss 2011</a>; <a href="./references#CD011551-bbs2-0041" title="KondziolkaD , LunsfordLD , MartinezAJ . Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low‐grade) astrocytoma. Journal of Neurosurgery1993;79:533‐6. [DOI: 10.3171/jns.1993.79.4.0533] ">Kondziolka 1993</a>; <a href="./references#CD011551-bbs2-0054" title="PiepmeierJM . Current concepts in the evaluation and management of WHO grade II gliomas. Journal of Neuro‐oncology2009;92(3):253‐9. [DOI: 10.1007/s11060‐009‐9870‐z] ">Piepmeier 2009</a>; <a href="./references#CD011551-bbs2-0063" title="ScottJN , BrasherPM , SevickRJ , RewcastleNB , ForsythPA . How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology2002;59(6):947‐9. [PUBMED: 12297589] ">Scott 2002</a>). Although LGGs are typically solid and non‐enhancing, HGGs may mimic this appearance in the ultra‐early stage of development (<a href="./references#CD011551-bbs2-0023" title="BarkerFG , 2nd , ChangSM , HuhnSL , DavisRL , GutinPH , McDermottMW , et al. Age and the risk of anaplasia in magnetic resonance‐nonenhancing supratentorial cerebral tumors. Cancer1997;80(5):936‐41. [PUBMED: 9307194] ">Barker 1997</a>; <a href="./references#CD011551-bbs2-0025" title="BernsteinM , GuhaA . Biopsy of low‐grade astrocytomas. Journal of Neurosurgery1994;80(4):776‐7. ">Bernstein 1994</a>; <a href="./references#CD011551-bbs2-0030" title="Cohen‐GadolAA , DiLunaML , BannykhSI , PiepmeierJM , SpencerDD . Non‐enhancing de novo glioblastoma: report of two cases. Neurosurgical Review2004;27(4):281‐5. [DOI: 10.1007/s10143‐004‐0346‐5] ">Cohen‐Gadol 2004</a>). Enhancement usually reflects a HGG but can be seen in some LGGs where it may indicate a more aggressive tumour (<a href="./references#CD011551-bbs2-0050" title="PalludJ , CapelleL , TaillandierL , FontaineD , MandonnetE , GuillevinR , et al. Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro‐oncology2009;11(2):176‐82. [DOI: 10.1215/15228517‐2008‐066] ">Pallud 2009</a>). Histological analysis is the most reliable method of diagnosing LGGs but requires a surgical procedure, either taking a small tissue sample for diagnostic purposes only (biopsy), or a larger tissue sample when removal of the tumour is attempted (resection). Both of these procedures are invasive and have a risk of adverse events. </p> </section> </section> <section id="CD011551-sec-0028"> <h3 class="title" id="CD011551-sec-0028">Index test(s)</h3> <section id="CD011551-sec-0029"> <h4 class="title">Magnetic resonance (MR) perfusion</h4> <p>Advanced MRI techniques could provide additional information on the aggressiveness of the tumour. One such technique that is becoming routinely employed in clinical centres is magnetic resonance (MR) perfusion, which identifies tumour angiogenesis or the proliferation of abnormal vessels in tumours. Tumoural vessels are tortuous, immature and leaky, and result in abnormal blood flow (haemodynamics) in the brain. On MR perfusion, these are depicted in colour maps of cerebral blood volume (CBV) and vessel wall permeability, which are quantitatively expressed as the ratio of tumoural CBV to normal‐appearing white matter CBV (relative CBV or rCBV), and the volume transfer constant <i>K</i><sup>trans</sup> (<a href="./references#CD011551-bbs2-0056" title="ProvenzaleJM , MukundanS , BarboriakDP . Diffusion‐weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology2006;239(3):632‐49. [DOI: 10.1148/radiol.2393042031] ">Provenzale 2006</a>), respectively. High‐grade tumours show increased CBV and increased <i>K</i><sup>trans</sup> on MR perfusion. </p> <p>Most studies utilising MR perfusion have been in the context of suspected HGGs (<a href="./references#CD011551-bbs2-0021" title="Al‐OkailiRN , KrejzaJ , WangS , WooJH , MelhemER . Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics2006;26(Suppl 1):S173‐89. [DOI: 10.1148/rg.26si065513] ">Al‐Okaili 2006</a>; <a href="./references#CD011551-bbs2-0010" title="LawM , YangS , WangH , BabbJS , JohnsonG , ChaS , et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR Imaging and Proton MR spectroscopic imaging compared with conventional MR imaging. AJNR. American Journal of Neuroradiology2003;24(10):1989‐98. [PUBMED: 14625221] ">Law 2003</a>; <a href="./references#CD011551-bbs2-0056" title="ProvenzaleJM , MukundanS , BarboriakDP . Diffusion‐weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology2006;239(3):632‐49. [DOI: 10.1148/radiol.2393042031] ">Provenzale 2006</a>). In this tumour group, MR perfusion can reliably demonstrate evidence of tumour angiogenesis, and an rCBV higher than 1.75 reliably associates with histological diagnosis (<a href="./references#CD011551-bbs2-0010" title="LawM , YangS , WangH , BabbJS , JohnsonG , ChaS , et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR Imaging and Proton MR spectroscopic imaging compared with conventional MR imaging. AJNR. American Journal of Neuroradiology2003;24(10):1989‐98. [PUBMED: 14625221] ">Law 2003</a>). However, the role of MR perfusion for the identification of suspected LGGs has not been described. Specifically, it is not known if MR perfusion can differentiate between grade II gliomas and grade III/IVtumours that otherwise may appear the same on standard MRI scans. </p> <p>Abnormalities on MR perfusion may also have a role in detecting grade transformation (increased malignancy) during follow‐up or as an independent biomarker of increased malignancy by itself, however neither of these roles were considered in this review. </p> </section> </section> <section id="CD011551-sec-0030"> <h3 class="title" id="CD011551-sec-0030">Clinical pathway</h3> <p><a href="#CD011551-fig-0001">Figure 1</a> summarises the pathway by which people with infiltrative gliomas are typically managed in the clinical setting. The role of imaging in the identification of primary disease as well as in surveillance for recurrence is incorporated. </p> <div class="figure" id="CD011551-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Diagram shows the clinical management algorithm for patients with infiltrative glioma. The role of the index test (MRP) for differentiating LGGs and HGGs at first presentation is shown with alternative tests (MRS, DWI, PET). These advanced MRI techniques are also used to identify progression or recurrence during interval scanning and are included, although they are outside the scope of this review. *May or may not be offered, depending on institutional/regional practice.Abbreviations: LGG: Low‐grade glioma, HGG: High‐grade glioma,MRP: Magnetic resonance perfusion, MRS: magnetic resonance spectroscopy, DWI: Diffusion‐weighted imaging, PET: Positron emission tomography" data-id="CD011551-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Diagram shows the clinical management algorithm for patients with infiltrative glioma. The role of the index test (MRP) for differentiating LGGs and HGGs at first presentation is shown with alternative tests (MRS, DWI, PET). These advanced MRI techniques are also used to identify progression or recurrence during interval scanning and are included, although they are outside the scope of this review. *May or may not be offered, depending on institutional/regional practice. </p> <p>Abbreviations: <b>LGG:</b> Low‐grade glioma, <b>HGG:</b> High‐grade glioma,<b>MRP:</b> Magnetic resonance perfusion, <b>MRS:</b> magnetic resonance spectroscopy, <b>DWI:</b> Diffusion‐weighted imaging, <b>PET:</b> Positron emission tomography </p> </div> </div> </div> <p>This review focuses on primary tumours, determining the accuracy of MR perfusion in differentiating LGGs from HGGs. Such characterisation may improve decision‐making towards conservative management or active treatment (surgery or chemotherapy/radiotherapy). </p> <section id="CD011551-sec-0031"> <h4 class="title">Prior test(s)</h4> <p>People, whether symptomatic or asymptomatic, are identified as having primary infiltrative gliomas on a standard contrast‐enhanced MRI scan as baseline imaging investigation. However MR alone is insufficient for definite classification into low grade or high grade. Typically, tumours that appear solid, non‐enhancing and associated with little mass effect are suspected to be LGGs, however occasionally HGGs may have the same appearance. </p> </section> <section id="CD011551-sec-0032"> <h4 class="title">Role of index test(s)</h4> <p>In addition to a standard contrast‐enhanced MRI scan, people with tumours may also undergo MR perfusion as part of their diagnostic work‐up, both of which are performed before surgery. The aim is to detect those tumours that are not LGGs but rather higher grade tumours on histology. </p> </section> <section id="CD011551-sec-0033"> <h4 class="title">Alternative test(s)</h4> <p>Other imaging methods can be used to increase the accuracy of diagnosing LGGs. These include other MRI techniques such as diffusion weighted imaging and magnetic resonance spectroscopy, and positron emission tomography. These methods may also play a role in predicting tumour grading but they are not included in this review. </p> </section> </section> <section id="CD011551-sec-0034"> <h3 class="title" id="CD011551-sec-0034">Rationale</h3> <p>Imaging features often play a major role in the initial management pathway of people with a brain tumour. There is interest in more accurate diagnosis and, in particular, in identifying when grade II tumours start to transform to grade III/IV tumours as early as possible in order to initiate treatment. If MR perfusion can reliably identify higher grade features in a tumour that otherwise appears like a grade II glioma on standard MRI scan, then possibly intervention would be more appropriate than a conservative 'watch‐and‐wait' approach. Conversely, if the MR perfusion findings reliably predict a grade II glioma, then a conservative 'watch‐and‐wait' approach could continue. </p> <p>Experience with MR perfusion is relatively limited and only a few large centres publish their own small case series. Interpretation is limited by variability in the conditions assessed and technical details of the scanning. To our knowledge, no previous reviews have tried to systematically analyse all available imaging studies on magnetic resonance perfusion for the diagnosis of solid and non‐enhancing LGGs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011551-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011551-sec-0035"></div> <p>To determine the diagnostic test accuracy of MR perfusion for identifying primary solid and non‐enhancing low‐grade (WHO Grade II) gliomas at first presentation in children and adults. In performing the quantitative analysis for this review, patients with LGGs were considered disease positive while patients with high‐grade (Grade III and IV) gliomas, being non‐LGGs, were considered as disease negative. </p> <section id="CD011551-sec-0036"> <h3 class="title" id="CD011551-sec-0036">Secondary objectives</h3> <p>To determine what clinical features and methodological features affect the accuracy of MR perfusion. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011551-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011551-sec-0037"></div> <section id="CD011551-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011551-sec-0039"> <h4 class="title">Types of studies</h4> <p>We included cross‐sectional studies with retrospective or prospective design, and excluded case‐control studies. Non‐English literature studies were eligible for inclusion. </p> </section> <section id="CD011551-sec-0040"> <h4 class="title">Participants</h4> <p>We considered studies that enrolled paediatric and adult patients with solid and non‐enhancing infiltrative tumours on standard contrast enhanced MRI and who had subsequent WHO grade histologic classification following biopsy or resection. The interval period between MR perfusion and histologic diagnosis must be within two months, as LGGs can transform into HGGs over that period of time. As this review focused on primary and not recurrent disease, participants who had received previous surgery (either biopsy or resection) or oncological treatment (chemotherapy or radiotherapy) prior to the index test were excluded. </p> </section> <section id="CD011551-sec-0041"> <h4 class="title">Index tests</h4> <p>Studies that employed dynamic susceptibility (DSC) and/or dynamic contrast‐enhanced (DCE) MR perfusion were considered for the review. They were included when data on rCBV and/or <i>K</i><sup>trans</sup> were provided, regardless of the method of acquisition, imaging analysis or post‐processing performed. Studies that used arterial spin labelling MR perfusion were excluded, as this method has been largely utilised as a research tool. </p> <p>For DSC MR perfusion, we adopted a common rCBV threshold of 1.75 following the landmark study of Law and colleagues (<a href="./references#CD011551-bbs2-0010" title="LawM , YangS , WangH , BabbJS , JohnsonG , ChaS , et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR Imaging and Proton MR spectroscopic imaging compared with conventional MR imaging. AJNR. American Journal of Neuroradiology2003;24(10):1989‐98. [PUBMED: 14625221] ">Law 2003</a>). This value is widely accepted and is used and recommended in clinical practice (<a href="./references#CD011551-bbs2-0021" title="Al‐OkailiRN , KrejzaJ , WangS , WooJH , MelhemER . Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics2006;26(Suppl 1):S173‐89. [DOI: 10.1148/rg.26si065513] ">Al‐Okaili 2006</a>). In this review, a positive test or rCBV &lt; 1.75 implied an LGG diagnosis while a negative test or rCBV &gt; 1.75 suggested an HGG diagnosis (<a href="./appendices#CD011551-sec-0073">Appendix 1</a>). With reference to the seven studies included in this review, five studies did not report an rCBV threshold, while the other two studies used or reported various rCBV thresholds (1.29, 1.5, 5.66). </p> <p>For DCE MR perfusion, there is no consensus in the field regarding a threshold. Only one out of seven included studies reported <i>K<sup>trans</sup> </i> and did not use a threshold. </p> <p>The generation of MR perfusion data is a multistep process involving acquisition, post‐processing and imaging analysis. Technical differences may arise at each step, which can ultimately influence the perfusion value obtained. Thus it is acknowledged that there may not be an appropriate single threshold when using multicentre MR perfusion data. </p> </section> <section id="CD011551-sec-0042"> <h4 class="title">Target conditions</h4> <p>The target condition is LGGs (disease positive in quantitative analysis), with the alternative condition being HGGs (i.e. non‐LGG or disease negative in quantitative analysis). Studies must have both conditions to be included in the review. </p> <p>We included studies that enrolled WHO Grade II diffuse astrocytomas, oligodendrogliomas and oligoastrocytomas, their Grade III anaplastic counterparts and glioblastomas (see <a href="#CD011551-tbl-0002">Table 1</a>). Other WHO Grade II‐IV gliomas of different histologic type were excluded, because they are rare and usually have distinct clinical characteristics. Grade I tumours were also excluded because their distinct clinical and radiological features separate their management from that of grade II tumours. In this review, gliomas were included irrespective of patient age and tumour location, although it is recognised that paediatric and adult gliomas, and supratentorial and brainstem gliomas may be histologically similar but have biologic and molecular differences (<a href="./references#CD011551-bbs2-0052" title="PaughBS , QuC , JonesC , LiuZ , Adamowicz‐BriceM , ZhangJ , et al. Integrated molecular genetic profiling of pediatric high‐grade gliomas reveals key differences with the adult disease. Journal of Clinical Oncology2010;28(18):3061‐8. [DOI: 10.1200/JCO.2009.26.7252] ">Paugh 2010</a>). </p> <div class="table" id="CD011551-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">World Health Organization (WHO) Grading of Brain Tumors*</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WHO Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tumour histology</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pilocytic astrocytoma</p> <p>Subependymal giant cell astrocytoma</p> <p>Pleomorphic xanthoastrocytoma</p> <p>Ganglioglioma</p> <p>Ependymoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diffuse astrocytoma</p> <p>Oligodendroglioma</p> <p>Oligoastrocytoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaplastic astrocytoma</p> <p>Anaplastic oligodendroglioma</p> <p>Anaplastic oligoastrocytoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glioblastoma multiforme</p> <p>Gliomatosis cerebri</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Partial listing and specific to the tumour histology types relevant to this review.</p> <p>**These tumours are included in this table for reference only and are not part of the review. </p> </div> </div> <p>Tumour histologies outside of these target conditions but having similar solid, non‐enhancing appearance as LGGs were recorded and excluded from the analysis. </p> </section> <section id="CD011551-sec-0043"> <h4 class="title">Reference standards</h4> <p>The reference standard is histological diagnosis assessed according to the WHO 2007 criteria (<a href="#CD011551-tbl-0002">Table 1</a>). We recorded the method of tumour sampling (biopsy or resection) per study. Reference test failures were treated as no histologic confirmation, and excluded from the analysis. </p> <p>There are two potential limitations with histology. First, histological diagnosis can be subjective and suffer from significant intra‐ and inter‐observer variability, even among neuropathologists (<a href="./references#CD011551-bbs2-0027" title="BratDJ , PraysonRA , RykenTC , OlsonJJ . Diagnosis of malignant glioma: role of neuropathology. Journal of Neuro‐oncology2008;89:287‐311. [DOI: 10.1007/s11060‐008‐9618‐1] ">Brat 2008</a>). Recently, the WHO classification (<a href="./references#CD011551-bbs2-0044" title="LouisDN , PerryA , ReifenbergerG , vonDeimlingA , Figarella‐BrangerD , CaveneeWK , et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica2016;131(6):803‐20. [DOI: 10.1007/s00401‐016‐1545‐1] ">Louis 2016</a>) has been substantially updated to incorporate molecular profiles in the diagnosis of diffuse gliomas, providing a layer of objectivity to tumour evaluation. However, these are not always available or reported, and were not used in this review. Second, tissue sampling is constrained by the surgical technique of tissue acquisition. Because gliomas are morphologically heterogeneous, they are susceptible to sampling errors, particularly in biopsies. Small volumes of tissue may not be representative of the most malignant component and are therefore less ideal compared with full tissue evaluation afforded by maximal resections. In fact, agreement in histological typing and grading between biopsies and resections has been found to be low (<a href="./references#CD011551-bbs2-0046" title="MuragakiY , ChernovM , MaruyamaT , OchiaiT , TairaT , KuboO , et al. Low‐grade glioma on stereotactic biopsy: how often is the diagnosis accurate?. Minimally Invasive Neurosurgery2008;51(5):275‐9. [DOI: 10.1055/s‐0028‐1082322] ">Muragaki 2008</a>). </p> </section> </section> <section id="CD011551-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <p>No language or document‐type restrictions were applied.</p> <section id="CD011551-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We performed a systematic search for literature with quantitative data. Articles were retrieved from the following electronic databases. </p> <p> <ol id="CD011551-list-0001"> <li> <p>MEDLINE via OvidSP (<a href="./appendices#CD011551-sec-0074">Appendix 2</a>, 1996 to 9 November 2016). </p> </li> <li> <p>Embase via OvidSP (<a href="./appendices#CD011551-sec-0075">Appendix 3</a>, 1996 to 9 November 2016). </p> </li> <li> <p><a href="http://login.webofknowledge.com/error/Error?Src=IP%26Alias=WOK5%26Error=IPError%26Params=%26PathInfo=%2F%26RouterURL=http%3A%2F%2Fwww.webofknowledge.com%2F%26Domain=.webofknowledge.com" target="_blank">Web of Science Core Collection</a>, specifically Science Citation Index Expanded and Conference Proceedings Citation Index ‐ Science via Thomson Reuters Web of Science (<a href="./appendices#CD011551-sec-0076">Appendix 4</a> 1990 to 9 November 2016). </p> </li> </ol> </p> <p>The search was restricted to studies in humans, and was limited to studies in the last 20 years, since MR perfusion is a relatively recent MRI technique. </p> </section> <section id="CD011551-sec-0046"> <h4 class="title">Searching other resources</h4> <p>Additional references were identified by manually searching the references of relevant review articles. We also used the 'related articles' feature in PubMed to identify articles similar in keywords and database subject headings to the original included studies. </p> <p>We sought unpublished studies by searching the conference proceedings, available online, of the following radiologic and neuroradiologic societies (years accessed). </p> <p> <ol id="CD011551-list-0002"> <li> <p>The Radiology Society of North America (2003 to 2016).</p> </li> <li> <p>The American Society of Neuroradiology (1996 to 2016).</p> </li> <li> <p>The European Society of Radiology (1999 to 2016).</p> </li> <li> <p>The European Society of Neuroradiology (1995 to 2016).</p> </li> </ol> </p> </section> </section> <section id="CD011551-sec-0047"> <h3 class="title" id="CD011551-sec-0047">Data collection and analysis</h3> <p>We followed the guidelines outlined in the <i>Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy</i> (<a href="./references#CD011551-bbs2-0045" title="MacaskillP , GatsonisC , DeeksJJ , HarbordRM , TakwoingiY . Chapter 10: Analysing and Presenting Results. In: DeeksJJ , BossuytPM , GatsonisC editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Ver 1.0, available from: http://srdta.cochrane.org/. The Cochrane Collaboration, 2010. ">Macaskill 2010</a>). </p> <section id="CD011551-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Prior to abstract review, two review authors (JMA, MGH) performed preliminary screening of titles to exclude irrelevant references. Subsequent screening was carried out by at least two authors (JMA, DMF, MGH, EKCL or JMP). Disagreements were resolved by consensus or third person. </p> <p>During the abstract review, potentially eligible publications were selected based on the following criteria. </p> <p> <ol id="CD011551-list-0003"> <li> <p>Did the study include participants suspected to have primary infiltrative gliomas (including LGG)? </p> </li> <li> <p>Were brain tumours confirmed by histology?</p> </li> <li> <p>Was MR perfusion performed?</p> </li> </ol> </p> <p>An initial review of full‐text publications was then conducted to establish that they meet the following criteria. </p> <p> <ol id="CD011551-list-0004"> <li> <p>Did the study enrol participants with solid non‐enhancing brain tumours on standard contrast‐enhanced MRI scan? </p> </li> <li> <p>Were measurements on rCBV and/or <i>K</i><sup>trans</sup> given? </p> </li> <li> <p>Can a two‐by‐two table be extracted from the provided data?</p> </li> </ol> </p> <p>When this information was not readily available from the published data, we contacted primary authors for clarification. In particular, information on the MRI appearance of the gliomas, i.e. if they were solid and non‐enhancing, and were not always explicitly reported in studies. We also requested for patient‐level data from authors to allow selection of tumours relevant to our review. The data included the individual perfusion values, the method of histologic confirmation, and interval period between the index test and histologic confirmation. </p> <p>Detailed data extraction of full‐text paper or conference abstract was carried out to determine final eligibility based on the inclusion criteria (see <a href="#CD011551-sec-0038">Criteria for considering studies for this review</a>). </p> </section> <section id="CD011551-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JMA, DMF) independently completed a data extraction form on all included studies. The following data were retrieved. </p> <p> <ol id="CD011551-list-0005"> <li> <p>General information: title, journal, year, publication status, and study design (prospective versus retrospective). </p> </li> <li> <p>Sample size: number of participants included, those meeting the target and alternative conditions (i.e. other‐gliomas and non‐gliomas), and reference test failures. </p> </li> <li> <p>Study setting: country and type of hospital.</p> </li> <li> <p>Baseline characteristics: age, sex.</p> </li> <li> <p>Clinical reference standard test: method of tissue sampling (biopsy or resection), blinding from MR perfusion results, interval period between MR perfusion and tissue diagnosis. </p> </li> <li> <p>Histologic diagnosis and WHO grade of tumour. In this review, LGGs are considered disease positive, and HGGs are disease negative. </p> </li> <li> <p>Details of the index test, including the strength of the MRI scanner, method of MR perfusion performed (DCE or DSC), pulse sequence, use of contrast preload, post‐processing algorithm, imaging analysis, blinding from histological analysis if retrospectively processed. </p> </li> <li> <p>Quantitative results of the index tests, including but not limited to rCBV, <i>K</i><sup>trans.</sup> </p> </li> <li> <p>Authors' recommended threshold.</p> </li> <li> <p>Number of true positive, false positive, true negative, false negative, and area under the receiver operating characteristic (ROC) curve, extracted based on authors' pre‐specified and recommended thresholds, and based on Law's threshold of 1.75. During the course of this review, we found that authors' pre‐specified and recommended thresholds were either missing or when available, heterogeneous, therefore we only used Law's threshold to construct the two‐by‐two contingency tables. A positive index test implied a diagnosis of LGG while a negative test suggested HGG. Thus, true positives are correctly diagnosed LGGs, false negatives are LGGs incorrectly labelled as HGG, true negatives are correctly diagnosed HGGs, while false positives are HGGs incorrectly labelled as LGG (<a href="./appendices#CD011551-sec-0073">Appendix 1</a>). </p> </li> </ol> </p> <p>We contacted primary authors via e‐mail for missing data and to obtain clarification on study methods. </p> </section> <section id="CD011551-sec-0050"> <h4 class="title">Assessment of methodological quality</h4> <p>Each study was assessed for methodological quality using the revised Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS 2) (<a href="./references#CD011551-bbs2-0068" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al. QUADAS 2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. [DOI: 10.7326/0003‐4819‐155‐8‐201110180‐00009] ">Whiting 2011</a>). QUADAS 2 assesses study quality through the use of signalling questions which facilitate assessment of risk of bias in four domains: patient sampling; index test; reference standard; and flow and timing. In addition, concerns regarding applicability were also rated in the first three domains. The QUADAS 2 tool for this review is described in <a href="./appendices#CD011551-sec-0077">Appendix 5</a> and was applied on study design and on the included patient data. To reduce uncertain risks, we sought clarification from authors when information was missing. e.g. blinding between MR perfusion and histology, details on the MRI acquisition and post‐processing. </p> <p>Summative data from QUADAS 2 were used to describe the numbers of studies with high/low/unclear risk of bias as well as concerns regarding applicability. All studies with sufficient data were included in the general analysis, but studies with low risk of bias in the domains of reference standard and flow and timing were used in the sensitivity analysis. </p> </section> <section id="CD011551-sec-0051"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>The reported number of true positive, false positive, false negative and true negative cases were used to construct two‐by‐two tables based on the author's pre‐specified and recommended thresholds, and Law's threshold. When these counts could not be determined from published data, we contacted authors for individual patient‐level data. </p> <p>Of the seven included studies, five studies did not report an rCBV threshold, while two studies pre‐specified or determined different rCBV thresholds (1.29, 1.5 and 5.66). One study used a pre‐specified threshold of 1.5, which was chosen as a mean between literature values (<a href="./references#CD011551-bbs2-0010" title="LawM , YangS , WangH , BabbJS , JohnsonG , ChaS , et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR Imaging and Proton MR spectroscopic imaging compared with conventional MR imaging. AJNR. American Journal of Neuroradiology2003;24(10):1989‐98. [PUBMED: 14625221] ">Law 2003</a>; <a href="./references#CD011551-bbs2-0070" title="ZonariP , BaraldiP , CrisiG . Multimodal MRI in the characterization of glial neoplasms: the combined role of singlevoxel MR spectroscopy, diffusion imaging and echo‐planar perfusion imaging. Neuroradiology2007;49:795–803. [DOI: 10.1007/s00234‐007‐0253‐x] ">Zonari 2007</a>). Thus, we used Law's threshold of 1.75 as a common threshold in the quantitative analysis for DSC perfusion, as this is more widely accepted in the field. Individual patient‐level data were classified using this common threshold to construct the two‐by‐two table per study. </p> <p>Meanwhile, of the seven included studies, only one study reported <i>K</i><sup>trans</sup> results, precluding quantitative analysis for DCE MR perfusion. </p> <p>Coupled forest plots showing pairs of sensitivity and specificity, with their 95% confidence intervals (CI), were constructed for each study using RevMan 5.3 (<a href="./references#CD011551-bbs2-0045" title="MacaskillP , GatsonisC , DeeksJJ , HarbordRM , TakwoingiY . Chapter 10: Analysing and Presenting Results. In: DeeksJJ , BossuytPM , GatsonisC editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Ver 1.0, available from: http://srdta.cochrane.org/. The Cochrane Collaboration, 2010. ">Macaskill 2010</a>; <a href="./references#CD011551-bbs2-0062" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). The Nordic Cochrane Centre, The Cochrane Collaboration,. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p>To estimate the summary sensitivity and specificity, we applied the bivariate model (<a href="./references#CD011551-bbs2-0061" title="ReitsmaJB , GlasAS , RutjesAW , ScholtenRJ , BossuytPM , ZwindermanAH . Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology2005;58(10):982‐90. [DOI: 10.1016/j.jclinepi.2005.02.022] ">Reitsma 2005</a>), which accounts for between‐study variability in estimates of sensitivity and specificity through the inclusion of random effects for the logit sensitivity and logit specificity parameters of the bivariate model. To generate the bivariate model parameters required to construct the SROC plot in Revman 5.3 (<a href="./references#CD011551-bbs2-0062" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). The Nordic Cochrane Centre, The Cochrane Collaboration,. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), the model was fitted using the lme4 package of R (<a href="./references#CD011551-bbs2-0057" title="R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R‐project.org/2013. ">R Core team 2013</a>) following <a href="./references#CD011551-bbs2-0051" title="PartlettC , TakwoingiY . Meta‐analysis of test accuracy studies in R: a summary of user‐written programs and step‐by‐step guide to using glmer. Version 1.0. Available from: http://methods.cochrane.org/sdt/August 2016. ">Partlett 2016</a>. </p> </section> <section id="CD011551-sec-0052"> <h4 class="title">Investigations of heterogeneity</h4> <p>As part of the secondary objective, we planned to investigate heterogeneity potentially arising from differences in participant characteristics and study design: </p> <p> <ol id="CD011551-list-0006"> <li> <p>tumour histology (subgroups for astrocytomas, oligodendrogliomas, and oligoastrocytomas);</p> </li> <li> <p>MRI strength (1.5T versus 3T);</p> </li> <li> <p>MR perfusion technique (DSC versus DCE);</p> </li> <li> <p>use of contrast preload;</p> </li> <li> <p>post‐processing technique (arterial input function versus gamma variate fitting; region of interest versus histogram analysis); </p> </li> <li> <p>method of histological sampling (biopsy versus resection).</p> </li> </ol> </p> <p>Due to the insufficient number of studies, we were unable to perform regression approach to explore heterogeneity. </p> <p>Subgroup analysis was conducted for tumour histology (astrocytomas versus oligodendrogliomas plus oligoastrocytomas) based on the bivariate model. As the data are sparse, the bootstrap method was used to compute the 95% confidence intervals for the estimates through the boot package of R (<a href="./references#CD011551-bbs2-0057" title="R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R‐project.org/2013. ">R Core team 2013</a>). Other subgroup analyses were not possible due to the small number of studies and participants. </p> </section> <section id="CD011551-sec-0053"> <h4 class="title">Sensitivity analyses</h4> <p>To determine the robustness of the outcome of the meta‐analysis, we conducted sensitivity analysis on good quality studies, defined as those with low risk of bias in domains 3 (reference standard) and 4 (flow and timing) as specified in the QUADAS 2 criteria (<a href="./appendices#CD011551-sec-0077">Appendix 5</a>). </p> <p>We also initially intended to conduct sensitivity analysis based on tumour status outside the target and alternative conditions (i.e. including other‐gliomas and non‐gliomas), but no data were available to perform this. </p> </section> <section id="CD011551-sec-0054"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not assess reporting bias as there are no clear‐cut methods to perform this for studies of diagnostic accuracy (<a href="./references#CD011551-bbs2-0028" title="BrazzelliM , LewisS , DeeksJJ , SandercockP . No evidence of bias in the process of publication of diagnostic accuracy studies in stroke submitted as abstracts. Journal of Clinical Epidemiology2009;62(4):425‐30. [DOI: 10.1016/j.jclinepi.2008.06.018] ">Brazzelli 2009</a>). It is noted that the index test under review is a widely available MRI technique and could be routinely employed in clinical practice (<a href="./references#CD011551-bbs2-0047" title="National Comprehensive Cancer Network. Central Nervous System Cancers (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns.pdfAccessed July 2017. ">NCCN Guidelines 2016</a>). As such, it would be unlikely to have a record of all attempted evaluations using this technique and therefore positive results are more likely to be reported in the literature (<a href="./references#CD011551-bbs2-0038" title="IrwigL , MacaskillP , GlasziouP , FaheyM . Meta‐analytic methods for diagnostic test accuracy. Journal of Clinical Epidemiology1995;48(1):119‐30. [PUBMED: 7853038] ">Irwig 1995</a>). To minimise this, we included radiology and neuroradiology conference proceedings in our literature search, where negative results could be documented which may not have been published. Further, the small number of included studies was also inadequate to assess reporting bias by funnel plot (<a href="./references#CD011551-bbs2-0032" title="DeeksJJ , MacaskillP , IrwigL . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Journal of Clinical Epidemiology2005;58:882–93. [DOI: 10.1016/j.jclinepi.2005.01.016] ">Deeks 2005</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011551-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011551-sec-0055"></div> <section id="CD011551-sec-0056"> <h3 class="title" id="CD011551-sec-0056">Results of the search</h3> <p>The study selection process is summarised in a PRISMA flow chart (<a href="#CD011551-fig-0002">Figure 2</a>). The literature search performed on 11 Nov 2016 identified 32,338 records, after de‐duplication and preliminary screening we identified 535 potentially relevant citations. After a further screening of titles and abstracts, we identified 19 studies for full‐text review. Of these, we excluded two which reported gliomas of mixed morphology that precluded selection of solid and non‐enhancing types (<a href="./references#CD011551-bbs2-0010" title="LawM , YangS , WangH , BabbJS , JohnsonG , ChaS , et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR Imaging and Proton MR spectroscopic imaging compared with conventional MR imaging. AJNR. American Journal of Neuroradiology2003;24(10):1989‐98. [PUBMED: 14625221] ">Law 2003</a>; <a href="./references#CD011551-bbs2-0018" title="SugaharaT , KorogiY , KochiM , IkushimaI , HiraiT , OkudaT , et al. Correlation of MR imaging‐determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR. American Journal of Roentgenology1998;171:1479‐86. [DOI: 10.2214/ajr.171.6.9843274] ">Sugahara 1998</a> ), two were excluded due to insufficient samples (no solid non‐enhancing HGGs) (<a href="./references#CD011551-bbs2-0014" title="RollinN , GuyotatJ , StreichenbergerN , HonnoratJ , Tran MinhVA , CottonF . Clinical relevance of diffusion and perfusionmagnetic resonance imaging in assessingintra‐axial brain tumors. Neuroradiology2006;48:150‐9. [DOI: 10.1007/s00234‐005‐0030‐7] ">Rollin 2006</a>; <a href="./references#CD011551-bbs2-0017" title="SentürkS , OğuzKK , CilaA . Dynamic contrast‐enhanced susceptibility‐weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner. Diagnostic and Interventional Radiology (Ankara, Turkey)2009;15(1):3‐12. [PUBMED: 19263367] ">Senturk 2009</a>), seven excluded due to an unclear time interval between the index test and reference standard (protocol specified less than two months) (<a href="./references#CD011551-bbs2-0008" title="FanGG , DengQL , WuZH , GuoQY . Usefulness of diffusion/perfusion‐weighted MRI in patients withnon‐enhancing supratentorial brain gliomas: a valuable tool topredict tumour grading?. British Journal of Radiology2006;79(944):652‐8. [DOI: 10.1259/bjr/25349497] ">Fan 2006</a>; <a href="./references#CD011551-bbs2-0009" title="GaudinoS , LorussoVS , CauloM , TartaroA , TartaglioneT , DiLellaG , et al. Multimodal MRI and overall diagnostic accuracy in non‐enhancing brain gliomas. Neuroradiology Journal. 2010; Vol. 23:145. ">Gaudino 2010</a>; <a href="./references#CD011551-bbs2-0011" title="LevMH , OzsunarY , HensonJW , RasheedAA , BarestGD , HarshGR4th , et al. Glial tumor grading and outcome prediction using dynamic spin‐echo MR susceptibility mapping compared with conventional contrast‐enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR. American Journal of Neuroradiology2004;25(2):214‐21. [PUBMED: 14970020] ">Lev 2004</a>; <a href="./references#CD011551-bbs2-0012" title="LiuX , TianW , KolarB , YeaneyGA , QiuX , JohnsonMD , et al. MR diffusion tensor and perfusion‐weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro‐oncology2011;13(4):447‐55. [DOI: 10.1093/neuonc/noq197] ">Liu 2011</a>; <a href="./references#CD011551-bbs2-0015" title="RomanoA , CoppolaV , CiprianiV , BonaminiM , TrasimeniG , FantozziLM , et al. Role of fractional anisotropy and RCBV in differential diagnosis between low grade oligodendrogliomas and anaplastic astrocitomas. Neuroradiology. 2011; Vol. 53:S36‐S37. ">Romano 2011</a>; <a href="./references#CD011551-bbs2-0016" title="SahinN , MelhemER , WangS , KrejzaJ , PoptaniH , ChawlaS , et al. Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion‐weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade. Neuroradiology2013;26(5):531–41. [DOI: 10.1177/197140091302600506] ">Sahin 2013</a>; <a href="./references#CD011551-bbs2-0019" title="WhitmoreRG , KrejzaJ , KapoorGS , HuseJ , WooJH , BloomS , et al. Prediction of oligodendroglial tumor subtype and grade usingperfusion weighted magnetic resonance imaging. Journal of Neurosurgery2007;107:600‐9. [DOI: 10.3171/JNS‐07/09/0600] ">Whitmore 2007</a>), and one excluded as no two‐by‐two table could be derived (<a href="./references#CD011551-bbs2-0013" title="MoritaN , WangS , ChawlaS , PoptaniH , MelhemER . Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas. Journal of Magnetic Resonance Imaging2010;32:803‐8. [DOI: 10.1002/jmri.22324] ">Morita 2010</a>). Thus seven studies met all inclusion criteria. </p> <div class="figure" id="CD011551-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD011551-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> </section> <section id="CD011551-sec-0057"> <h3 class="title">Methodological quality of included studies</h3> <p>We judged the methodological qualities of each of the seven included studies according to the modified QUADAS‐2 criteria (<a href="./appendices#CD011551-sec-0077">Appendix 5</a>) and the results are presented in the respective sections below and summarised in <a href="#CD011551-fig-0003">Figure 3</a> and <a href="#CD011551-fig-0004">Figure 4</a>. Often the research questions of the accepted studies did not match our review question, and we assessed studies for their risk of bias and concerns regarding applicability based on the study design and the extracted included patient data. </p> <div class="figure" id="CD011551-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study using QUADAS 2 tool, applied on study design and included patient data" data-id="CD011551-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study using QUADAS 2 tool, applied on study design and included patient data </p> </div> </div> </div> <div class="figure" id="CD011551-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies" data-id="CD011551-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies </p> </div> </div> </div> <p>Only one study had low risk of bias and low concern for applicability across all domains (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>). Five studies had low risk of bias in the domains of reference standard and flow &amp; timing and were deemed of good quality (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>). </p> <section id="CD011551-sec-0058"> <h4 class="title">Participant Selection</h4> <p>Risk of bias for participant selection was low in five out of seven studies (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>). The other two studies had high risk due to unclear patient sampling (<a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>) and inappropriate exclusion of small tumours (<a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>). Although many studies had different objectives from our review and also reported contrast enhancing tumours and Grade 1 gliomas, by extracting patient‐level data from many authors, we were able to select participants with the target and alternative conditions only. Thus concerns of applicability with regard to participant selection were low. </p> </section> <section id="CD011551-sec-0059"> <h4 class="title">Index test</h4> <p>The highest level of risk of bias was observed in the index test domain, with six studies lacking use of a pre‐specified threshold. Only one study used a pre‐specified rCBV threshold of 1.5 (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>), which was chosen as a mean between literature values (<a href="./references#CD011551-bbs2-0010" title="LawM , YangS , WangH , BabbJS , JohnsonG , ChaS , et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR Imaging and Proton MR spectroscopic imaging compared with conventional MR imaging. AJNR. American Journal of Neuroradiology2003;24(10):1989‐98. [PUBMED: 14625221] ">Law 2003</a>; <a href="./references#CD011551-bbs2-0070" title="ZonariP , BaraldiP , CrisiG . Multimodal MRI in the characterization of glial neoplasms: the combined role of singlevoxel MR spectroscopy, diffusion imaging and echo‐planar perfusion imaging. Neuroradiology2007;49:795–803. [DOI: 10.1007/s00234‐007‐0253‐x] ">Zonari 2007</a>). However, this limitation in study design was overcome by using individual patient‐level data, which allowed use of a common rCBV threshold of 1.75 for the quantitative analyses. Meanwhile, in one study it was unclear if the index test was interpreted without knowledge of the results of the reference standard (<a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>). Concerns for applicability with regard to the index test were low, with good evidence in all included studies to suggest MR perfusion was performed in a way similar to clinical practice. </p> </section> <section id="CD011551-sec-0060"> <h4 class="title">Reference standard</h4> <p>Reference standard issues were present in two studies, due to uncertainties regarding the blinding of interpretation (<a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>; <a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>). All studies based tumour grading on histopathological assessment. Concerns for applicability with regard to reference standard domains were generally low, with one study deemed high concern due to an unclear description of the proportions of patients undergoing a resection or biopsy (<a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>). </p> </section> <section id="CD011551-sec-0061"> <h4 class="title">Flow and timing</h4> <p>There were no flow and timing issues. In all studies, patients underwent either biopsy or resection irrespective of the results of the index test. Only patients with an interval period of less than two months between the index test and reference standard were included in the analysis. </p> </section> </section> <section id="CD011551-sec-0062"> <h3 class="title" id="CD011551-sec-0062">Findings</h3> <p>Seven studies were included; one study met inclusion criteria based on published data alone (<a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>), while the other six were confirmed to meet inclusion criteria after obtaining patient‐level data and/or clarification from authors (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016;</a><a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a><a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>). Collectively, the seven studies reported 392 patients with brain tumours/gliomas, however only 124 were confirmed to be primary and untreated solid and non‐enhancing WHO grade II‐IV gliomas, and of these, only 115 underwent tissue sampling within 2 months of MR perfusion and were included in the review. The sample size per study was generally small and ranged from 4 to 48 cases, and only 2 studies had sample sizes of more than 20 (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>). The limited available evidence restricts the conclusions that can be drawn from the review. </p> <p>All seven studies reported rCBV, which allowed quantitative analysis for DSC MR perfusion. Meanwhile, only one study reported <i>K</i><sup>trans</sup> (<a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>,) which precluded quantitative analysis for DCE MR perfusion. </p> <p>The included studies originated from Europe (Italy, Sweden, Spain and France), Asia (two studies from Japan) and South America (one from Brazil). All avoided case‐control design. One study was retrospective (<a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>), while the rest were prospectively performed. The studies were mostly conducted in university hospitals save for one study (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>). The studies recruited mostly adults (only <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a> specifically recruited paediatric participants). </p> <p>Most patients underwent resection and only a small proportion underwent biopsy for tissue diagnosis. Histologic confirmation was via resection only in three studies (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>), mix of resection (predominant) and biopsy in three studies (<a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>), and was unspecified in one study (<a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>). </p> <p>The majority of MRI scans were performed on a 1.5T scanner (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>; <a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>); two studies used a 3T scanner (<a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>). All studies performed DSC MR perfusion and provided rCBV results. Other DSC MR perfusion‐derived quantitative measures such as cerebral blood flow and apparent transfer constant were additionally reported by one study (<a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>), which was also the only study that performed DCE MR perfusion and provided <i>K</i><sup>trans</sup>. Contrast preloading was used in two studies (<a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>), but not in four studies (<a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014;</a><a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016;</a><a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004;</a><a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>), while it was not reported in one study (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>). The post‐processing algorithm was reported in all studies; four studies used arterial input function (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016;</a><a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>); two used gamma variate function (<a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>), and one used area under the curve analysis (<a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>). All studies employed region of interest (ROI) method to obtain perfusion values in areas showing high perfusion, and one study (<a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>) provided histogram results from the ROI's drawn. </p> <p>Individual perfusion values were published in two studies (<a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>; <a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>) and were provided by authors in the other five studies (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>). From these published and unpublished data, a total of 124 solid and non‐enhancing gliomas were identified, of which 115 (83 LGGs, 32 HGGs) met all inclusion criteria and were selected for the review. </p> <p>The average rCBV per tumour grade and tumour histology in each included study are summarised in <a href="#CD011551-tbl-0003">Table 2</a>. Most studies recruited Grade II and III gliomas, with only one case of a solid and non‐enhancing Grade IV/glioblastoma with rCBV of 0.3 (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>). All tumours were graded using the WHO classification, and in this review LGG was classified as disease positive, and HGG as disease negative for the quantitative analysis. Histology was available in all of them except for two of the four included cases from <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>. Diffuse astrocytomas were reported in the remainder of the studies, and other tumour histology types were not always represented per study. Other tumours with solid and non‐enhancing appearance on MRI but with histology different from the target and alternative conditions were reported and excluded in two studies (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>). </p> <div class="table" id="CD011551-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">rCBV per tumour grade and per tumour histology</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included studies</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LGG</p> <p>(Grade II)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGG</p> <p>(Grade III+IV)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OG</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AOA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AOG</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 ± 0.95</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 + 0.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 ± 0.76</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 ± 1.13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 ± 0.57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 ± 0.53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 ± 0.98</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 + 0.48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 + 0.93</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 + 0.69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 + 0.21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 + 0.32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22 + 1.18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 + 0.79</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 + 0.29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 ±1.33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 + 0.04</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 + 0.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>[0.77]</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>[0.41]</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 ± 1.19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.83 ± 2.34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.31 ±1.23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.88 ±.46</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 + 2.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 ± 0.63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2 ± 0.35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9 ±.43</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.98 ± 0.57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.24 ± 0.37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.99</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 ± 0.17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 ± 0.08</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 ± 0.17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>LGG:</b> Low‐grade glioma, <b>HGG:</b> high‐grade glioma, <b>DA:</b> diffuse astrocytoma, <b>OA:</b> oligoastrocytoma, <b>OG:</b> oligodendroglioma, <b>AA:</b> anaplastic astrocytoma, <b>AOA:</b> Anaplastic oligoastrocytoma, <b>AOG:</b> anaplastic oligodendroglioma. </p> <p>Nearly all HGGs are Grade III, except for one case of Grade IV/glioblastoma from <a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>, with rCBV of 0.3. Bracketed values in <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a> are included for completion but represent unspecified gliomas, with no reported histology. </p> </div> </div> <p>The average rCBV (range) per glioma grade and histology with their numbers are 1.29 (0.01 to 5.10) for LGGs (N = 83), 1.89 (0.30 to 6.51) for HGGs (N = 32). Average rCBV was 1.19 (0.34 to 3.72) for Grade II astrocytomas (N = 40), 1.63 (0.01 to 4.30) for Grade II oligodendrogliomas (N = 19), 1.22 (0.08 to 5.10) for Grade II oligoastrocytomas (N = 23). The rCBV for combined Grade II oligodendroglioma + oligoastrocytoma was 1.41 (0.01 to 5.10) (N = 42); 2.02 (0.65 to 3.79) for Grade III astrocytomas (N = 15), 2.99 (1.70 to 6.51) for Grade III oligodendrogliomas (N = 4); 1.44 (0.60 to 3.34) for Grade III oligoastrocytomas (N = 11) and 1.96 (0.60 to 6.51) for combined Grade III oligodendrogliomas+oligoastrocytomas (N = 15). </p> <p>Only one study (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>) used a pre‐specified rCBV threshold, and chose 1.5 as a mean between literature threshold values (<a href="./references#CD011551-bbs2-0010" title="LawM , YangS , WangH , BabbJS , JohnsonG , ChaS , et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR Imaging and Proton MR spectroscopic imaging compared with conventional MR imaging. AJNR. American Journal of Neuroradiology2003;24(10):1989‐98. [PUBMED: 14625221] ">Law 2003</a>; <a href="./references#CD011551-bbs2-0070" title="ZonariP , BaraldiP , CrisiG . Multimodal MRI in the characterization of glial neoplasms: the combined role of singlevoxel MR spectroscopy, diffusion imaging and echo‐planar perfusion imaging. Neuroradiology2007;49:795–803. [DOI: 10.1007/s00234‐007‐0253‐x] ">Zonari 2007</a>). Two studies determined rCBV thresholds for differentiating LGGs and HGGs: 1.29 (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>) and 5.66 (<a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>). The other five studies did not determine an rCBV threshold (<a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014;</a><a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>, <a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>). Because of the lack or variability of thresholds reported by studies, we adopted the widely accepted rCBV value of 1.75 as common threshold for the quantitative analysis of DSC MR perfusion. In this review, an rCBV &lt; 1.75 was classified as test positive and implied a diagnosis of LGG, while an rCBV &gt; 1.75 was classified as test negative and suggested a diagnosis of HGG. Thus in constructing the two‐by‐two contingency tables, true and false positives represented the number of LGGs correctly and incorrectly diagnosed, respectively, while true and false negatives represented the number of HGGs correctly and incorrectly diagnosed, respectively (<a href="./appendices#CD011551-sec-0073">Appendix 1</a>). </p> <p>The sensitivity and specificity of the seven included studies are presented in coupled forest plots in <a href="#CD011551-fig-0005">Figure 5</a>. Sensitivity estimates were generally in the upper range and had wide confidence intervals. Mean sensitivities were &gt; 0.70 in six out of seven studies (excepting <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>). Of these, two studies with a mean sensitivity of 1.00 had very wide confidence intervals, and were derived from studies with the smallest sample size of four each (<a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>, <a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>). In contrast, two studies with the largest sample sizes of 48 and 21 had mean sensitivities of 0.82 and 0.93 (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a> and <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>, respectively) with moderately wide confidence intervals. Meanwhile, mean specificities were quite heterogeneous and showed even wider confidence intervals. The two largest studies of <a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a> and <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a> had opposing mean specificity values of 0.21 and 1.00, respectively. </p> <div class="figure" id="CD011551-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Coupled forest plots of included studies using rCBV threshold of &lt; 1.75 for differentiating low grade gliomas from high‐grade gliomas." data-id="CD011551-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Coupled forest plots of included studies using rCBV threshold of &lt; 1.75 for differentiating low grade gliomas from high‐grade gliomas. </p> </div> </div> </div> <p>Meta‐analysis of the seven studies using a bivariate model yielded a summary sensitivity and specificity of 0.83 (95% CI 0.66 to 0.93) and 0.48 (95% CI 0.09 to 0.90), respectively (<a href="#CD011551-fig-0006">Figure 6</a>). The 95% confidence ellipse of the summary point is quite wide and spans the upper half of the range of sensitivity, and spans nearly the entire range of specificity. </p> <div class="figure" id="CD011551-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Summary ROC Plot of DSC MR perfusion using rCBV threshold of 1.75 for differentiating low grade gliomas from high‐grade gliomas. In this review, a positive test or rCBV &lt; 1.75 implied an LGG diagnosis, while a negative test or rCBV &gt; 1.75 suggested an HGG diagnosis. In the SROC plot, each study is represented by an open circle with emanating lines, representing the sensitivity and specificity with their confidence intervals. The size of the open circle is proportional to the study sample size. The shaded circle represents the pooled sensitivity and specificity surrounded by a 95% confidence ellipse (dotted line), which in this case is 0.830 (95% CI 0.657, 0.926) and 0.479 (95% CI 0.086, 0.900), respectively." data-id="CD011551-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC Plot of DSC MR perfusion using rCBV threshold of 1.75 for differentiating low grade gliomas from high‐grade gliomas. In this review, a positive test or rCBV &lt; 1.75 implied an LGG diagnosis, while a negative test or rCBV &gt; 1.75 suggested an HGG diagnosis. In the SROC plot, each study is represented by an open circle with emanating lines, representing the sensitivity and specificity with their confidence intervals. The size of the open circle is proportional to the study sample size. The shaded circle represents the pooled sensitivity and specificity surrounded by a 95% confidence ellipse (dotted line), which in this case is 0.830 (95% CI 0.657, 0.926) and 0.479 (95% CI 0.086, 0.900), respectively. </p> </div> </div> </div> <p>Regression analysis to explore heterogeneity was not performed due to insufficient data. </p> <p>Subroup analysis on tumour histology types showed summary sensitivities and specificities of 0.92 (95% CI 0.55 to 0.99) and 0.42 (95% CI 0.02 to 0.95) respectively, for astrocytomas using data from six studies (55 participants) (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>; <a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a>), and 0.77 (95% CI 0.46 to 0.93) and 0.53 (95% CI 0.14 to 0.88), respectively, for combined oligodendrogliomas+oligoastrocytomas using data from six studies (56 participants) (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>). </p> <p>Additional subgroup analysis on other variables such as histologic confirmation method, MRI acquisition and post‐processing could not be performed due to limited data. </p> <p>Sensitivity analysis using five good quality studies (107 participants: 79 LGG, 28 HGG) with low risk of bias in the domains of reference standard and flow and timing resulted in summary sensitivity of 0.80 (95% CI 0.61 to 0.91) and summary specificity of 0.67 (95% CI 0.07 to 0.98) (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>; <a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a>). </p> <p>Overall, the individual studies and meta‐analysis yielded variable and/or wide‐ranging estimates which are attributed to the small sample sizes. Thus currently, the diagnostic accuracy of MR perfusion cannot be reliably determined based on the available data. Insufficient data also precluded determination of clinical and methodological factors affecting the accuracy of MR perfusion. </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011551-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011551-sec-0063"></div> <p>In this review, we determined the accuracy of magnetic resonance (MR) perfusion for differentiating primary untreated low‐grade gliomas (LGGs) from high‐grade gliomas (HGGs), when they appear as solid and non‐enhancing on standard magnetic resonance imaging (MRI). While MR perfusion is becoming increasingly commonly used in clinical practice and regarded to be an integral technique in current brain tumour imaging (<a href="./references#CD011551-bbs2-0066" title="WelkerK , BoxermanJ , KalninA , KaufmannT , ShiroishiM , WintermarkM , American Society of Functional Neuroradiology MR Perfusion Standards and Practice Subcommittee of the ASFNR Clinical Practice Committee. ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain. AJNR. American Journal of Neuroradiology2015;36(6):E41‐51. [DOI: 10.3174/ajnr.A4341] ">Welker 2015</a>), we found limited evidence regarding its diagnostic performance for grading solid and non‐enhancing diffuse gliomas. There were insufficient data to determine the clinical and methodological features that affect the accuracy of this technique. The conclusions that can be drawn from the review are therefore restricted. </p> <section id="CD011551-sec-0064"> <h3 class="title" id="CD011551-sec-0064">Summary of main results</h3> <p>Seven studies were included and all but one were prospectively carried out. All studies reported CBV ratio of tumour (rCBV) and only one reported <i>K<sup>trans</sup> </i>, limiting this review to DSC MR perfusion only. While most examined the diagnostic accuracy of MR perfusion, pre‐specified thresholds were not commonly used, and thresholds were either not determined or varied; thus we applied a common rCBV threshold of 1.75 for the quantitative analysis. The acquisition and post‐processing of MR perfusion were moderately heterogeneous, with different scanner magnetic field strengths employed (1.5 and 3T), different pulse sequences (spin echo and gradient echo), use and non‐use of contrast preload, and different post‐processing algorithms (arterial input function, gamma variate function and area under the curve). This may reflect the difficulties of implementing a single standard in clinical practice, or a lack of evidence for any given protocol, but may also make problematic the use of a single threshold when handling multicentre perfusion data. Subsequent analysis was similar, with predominant use of the region of interest (ROI) method to obtain rCBV, and targeting of tumour regions that show high perfusion. The majority of tumours were resected, allowing a more definitive reference standard. </p> <p>From published data and unpublished results from authors, we were able to identify 115 solid and non‐enhancing gliomas that met all the inclusion criteria and allowed quantitative analysis for dynamic susceptibility (DSC) MR perfusion. The studies generally had small sample sizes (range of 4 to 48). Meta‐analysis identified that estimates for both mean sensitivity and specificity were very uncertain so evidence of diagnostic performance is unreliable. This is identified from the wide confidence intervals for the estimates of sensitivity and specificity: sensitivity 0.83 (95% CI 0.66 to 0.93) and specificity of 0.48 (95% CI 0.09 to 0.90). Sensitivity analysis using good quality studies and subgroup analysis on tumour histology produced consistent results; i.e. sensitivity and specificity cannot be reliably estimated based on small number of patients in the included studies. Regression analysis to explore heterogeneity also could not be performed due to insufficient data. </p> <p>Thus, from the currently reviewed evidence, we cannot reliably estimate specificity from meta‐analysis as although the average estimate is 48%, from the 95% CI the value could be as low as 9% or as high as 90%. Sensitivity is also poorly estimated with an average of 83%, but with estimates potentially including values ranging from 66% to 93%. </p> <p>A precis of these findings, together with the study quality assessment, are presented in the <a href="./full#CD011551-tbl-0001">summary of findings Table</a>. </p> <p>Our meta‐analysis on 83 LGGs and 32 HGGs suggest that DSC MR perfusion performance cannot be reliably estimated based on current evidence for either sensitivity or specificity for the identification of primary and untreated, solid and non‐enhancing WHO grade II gliomas from higher grade gliomas. Additionally, the limited available data also preclude assessment on how other clinical and methodological features affect the accuracy of MR perfusion. Future research would need to include a much larger sample size of patients with both LGG and HGG, preferably using a standardised scanning protocol to reliably estimate performance of MR perfusion. A recent paper demonstrates that standardised acquisition and analysis for MR perfusion in a multicentre clinical setting is feasible, and derived an rCBV threshold of 3.33 to differentiate Grade II from III/IV gliomas (<a href="./references#CD011551-bbs2-0022" title="AnzaloneN , CastellanoA , CadioliM , ConteGM , CuccariniV , BizziA , et al. A multi‐center, standardized assessment of dynamic contrast‐enhanced and dynamic susceptibility contrast MRI in grading gliomas. Radiology2017 (in press). ">Anzalone 2017</a>). </p> </section> <section id="CD011551-sec-0065"> <h3 class="title" id="CD011551-sec-0065">Strengths and weaknesses of the review</h3> <p>One study (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>) closely mirrored the patient population and study design considered to be appropriate for studies of diagnostic accuracy. Also, most of the included studies were prospective in design and performed resection, which allowed a more definitive histologic diagnosis to serve as reference standard. The small number of included studies poses a limitation but this is a reflection of strict methodological standards required to remain faithful to the review question. During the screening process, we encountered many studies that performed MR perfusion for glioma grading, however they could not be included because often the MRI appearances of the tumour could not be ascertained or the perfusion values of such solid and non‐enhancing gliomas were not specifically reported. Many authors were contacted and invited to share their data by which we were able to include unpublished perfusion values from five studies in the meta‐analysis (<a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>; <a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a>; <a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a>; <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a>; <a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a>). Overall, performing a meta‐analysis has allowed a thorough critique of the methodological quality of studies in the literature, and a substantially larger number of participants to base conclusions upon than any one single study. However, the included number of patients (115) remains small and limits the conclusions that can be drawn from this review. </p> </section> <section id="CD011551-sec-0066"> <h3 class="title" id="CD011551-sec-0066">Applicability of findings to the review question</h3> <p>Based on a small number of participants, the estimated sensitivity suggests that DSC MR perfusion may be able to detect up to 93% of patients with LGG, but sensitivity can be as low as 66%. Thus, between 7% and 34% of patients with LGG may have MR perfusion findings suggestive of HGG, and patients may feel compelled to undergo early intervention. In this instance one option could be to perform an early diagnostic biopsy, which can be performed with little morbidity (<a href="./references#CD011551-bbs2-0042" title="KrethFW , MuacevicA , MedeleR , BiseK , MeyerT , ReulenHJ . The risk of haemorrhage after image guided stereotactic biopsy of intra‐axial brain tumours—a prospective study. Acta Neurochirurgica (Wien)2001;143:539–45. [PUBMED: 11534670] ">Kreth 2001</a>), but risks undersampling and falsely undergrading the tumour (<a href="./references#CD011551-bbs2-0046" title="MuragakiY , ChernovM , MaruyamaT , OchiaiT , TairaT , KuboO , et al. Low‐grade glioma on stereotactic biopsy: how often is the diagnosis accurate?. Minimally Invasive Neurosurgery2008;51(5):275‐9. [DOI: 10.1055/s‐0028‐1082322] ">Muragaki 2008</a>). Another option would be to consider aggressive surgical resection as is typically performed in HGG, for example with fluorescence or intra‐operative MRI guidance. This could potentially differ from the surgical approach offered in LGG where one might prefer awake craniotomy with functional brain mapping. A further option would be a further standard MRI scan with rCBV after a short time interval, as earlier intervention has not been widely shown yet to extend survival in LGG or asymptomatic transforming LGG and repeat scan may add further weight regarding whether or not to intervene. </p> <p>Both surgical options will allow histologic confirmation but perhaps more importantly, provide a molecular profile of the tumour. The recent major restructuring of the WHO classification for brain tumours (<a href="./references#CD011551-bbs2-0044" title="LouisDN , PerryA , ReifenbergerG , vonDeimlingA , Figarella‐BrangerD , CaveneeWK , et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica2016;131(6):803‐20. [DOI: 10.1007/s00401‐016‐1545‐1] ">Louis 2016</a>) now establishes primacy of the incorporation of molecular genetic features with histology in tumour diagnosis, prognostication and therapy guidance. Following suit, the European Association for Neuro‐Oncology (EANO) have recently issued treatment guidelines based on this integrated phenotype‐genotype classification and recommends diagnostic biopsy at minimum, excepting high‐risk cases and those with unfavourable prognosis where treatment is unlikely to be successful (<a href="./references#CD011551-bbs2-0067" title="WellerM , van denBentM , TonnJC , StuppR , PreusserM , Cohen‐Jonathan‐MoyalE , et al. European Association for Neuro‐Oncology (EANO) Task Force on Gliomas. European Association for Neuro‐Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology2017;6:e315‐e329. [DOI: 10.1016/S1470‐2045(17)30194‐8] ">Weller 2017</a>). </p> <p>Meanwhile the estimated specificity of MR perfusion is more heterogeneous: 9% to 90%. This means that between 10% and 91% of cases of HGGs may be labelled as LGGs and patients may decide for a watch‐and‐wait approach. This would lead to delay in performing resection, when this would have been the strongly recommended initial treatment approach for people with surgically accessible HGG (<a href="./references#CD011551-bbs2-0033" title="DietrichJ . Clinical presentation, initial surgical approach, and prognosis of high‐grade gliomas. www.uptodate.com (Accessed on December 17, 2017). ">Dietrich 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011551-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/urn:x-wiley:14651858:media:CD011551:CD011551-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_t/tCD011551-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Diagram shows the clinical management algorithm for patients with infiltrative glioma. The role of the index test (MRP) for differentiating LGGs and HGGs at first presentation is shown with alternative tests (MRS, DWI, PET). These advanced MRI techniques are also used to identify progression or recurrence during interval scanning and are included, although they are outside the scope of this review. *May or may not be offered, depending on institutional/regional practice.Abbreviations: LGG: Low‐grade glioma, HGG: High‐grade glioma,MRP: Magnetic resonance perfusion, MRS: magnetic resonance spectroscopy, DWI: Diffusion‐weighted imaging, PET: Positron emission tomography" data-id="CD011551-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Diagram shows the clinical management algorithm for patients with infiltrative glioma. The role of the index test (MRP) for differentiating LGGs and HGGs at first presentation is shown with alternative tests (MRS, DWI, PET). These advanced MRI techniques are also used to identify progression or recurrence during interval scanning and are included, although they are outside the scope of this review. *May or may not be offered, depending on institutional/regional practice. </p> <p>Abbreviations: <b>LGG:</b> Low‐grade glioma, <b>HGG:</b> High‐grade glioma,<b>MRP:</b> Magnetic resonance perfusion, <b>MRS:</b> magnetic resonance spectroscopy, <b>DWI:</b> Diffusion‐weighted imaging, <b>PET:</b> Positron emission tomography </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011551-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/urn:x-wiley:14651858:media:CD011551:CD011551-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_t/tCD011551-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD011551-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011551-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/urn:x-wiley:14651858:media:CD011551:CD011551-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_t/tCD011551-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study using QUADAS 2 tool, applied on study design and included patient data" data-id="CD011551-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study using QUADAS 2 tool, applied on study design and included patient data </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011551-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/urn:x-wiley:14651858:media:CD011551:CD011551-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_t/tCD011551-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies" data-id="CD011551-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011551-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/urn:x-wiley:14651858:media:CD011551:CD011551-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_t/tCD011551-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Coupled forest plots of included studies using rCBV threshold of &lt; 1.75 for differentiating low grade gliomas from high‐grade gliomas." data-id="CD011551-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Coupled forest plots of included studies using rCBV threshold of &lt; 1.75 for differentiating low grade gliomas from high‐grade gliomas. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011551-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/urn:x-wiley:14651858:media:CD011551:CD011551-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_t/tCD011551-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Summary ROC Plot of DSC MR perfusion using rCBV threshold of 1.75 for differentiating low grade gliomas from high‐grade gliomas. In this review, a positive test or rCBV &lt; 1.75 implied an LGG diagnosis, while a negative test or rCBV &gt; 1.75 suggested an HGG diagnosis. In the SROC plot, each study is represented by an open circle with emanating lines, representing the sensitivity and specificity with their confidence intervals. The size of the open circle is proportional to the study sample size. The shaded circle represents the pooled sensitivity and specificity surrounded by a 95% confidence ellipse (dotted line), which in this case is 0.830 (95% CI 0.657, 0.926) and 0.479 (95% CI 0.086, 0.900), respectively." data-id="CD011551-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Summary ROC Plot of DSC MR perfusion using rCBV threshold of 1.75 for differentiating low grade gliomas from high‐grade gliomas. In this review, a positive test or rCBV &lt; 1.75 implied an LGG diagnosis, while a negative test or rCBV &gt; 1.75 suggested an HGG diagnosis. In the SROC plot, each study is represented by an open circle with emanating lines, representing the sensitivity and specificity with their confidence intervals. The size of the open circle is proportional to the study sample size. The shaded circle represents the pooled sensitivity and specificity surrounded by a 95% confidence ellipse (dotted line), which in this case is 0.830 (95% CI 0.657, 0.926) and 0.479 (95% CI 0.086, 0.900), respectively. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011551-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/urn:x-wiley:14651858:media:CD011551:CD011551-TST-001" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_t/tCD011551-TST-001.xxx" target="_blank"><b></b></a></p> </div><img alt="rCBV ‐ Law Threshold." data-id="CD011551-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-TST-001.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>rCBV ‐ Law Threshold.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/references#CD011551-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/media/CDSR/CD011551/image_n/nCD011551-TST-001.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011551-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Summary of findings table</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Population</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Almost all adults</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Setting</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Mostly university hospitals, employing exclusively 1.5T or 3T MRI scanners</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index test</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Dynamic susceptibility contrast MR perfusion (commonly gradient echo rather than spin echo sequence acquisition), usually without contrast preload, typically using arterial input function or gamma variate function post‐processing algorithms, and preferentially using region‐of‐interest method to obtain Max rCBV values (CBV ratio of tumour: contralateral normal appearing white matter) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Importance</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>For solid and non‐enhancing brain tumours with low rCBV, patients with no or little neurologic deficit may opt for conservative management over surgery to avoid early neurologic disability. Meanwhile, patients with high rCBV could favour early treatment for better tumour control. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reference standard</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>All with histologic examinations, majority with resection.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Mostly prospective cross sectional studies (no case‐control studies)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Positive Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Summary accuracy<br/> (95% CI) using bivariate model </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No. of study participants / selected patients<br/> (No. of studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Implications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of studies<br/> (Based on QUADAS‐2 applied on study design and selected patients) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comments</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rCBV threshold &lt;1.75 indicates LGG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity</p> <p>(proportion of LGG detected by MR perfusion)</p> <p>0.83</p> <p>(0.66, 0.93)<br/> <br/> Specificity </p> <p>(proportion of HGG detected by MR perfusion)</p> <p>0.48</p> <p>(0.09 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>392 patients /</p> <p>115 with solid non‐enhancing Grade II‐IV gliomas who underwent tissue sampling within 2 months of MR perfusion </p> <p>(7 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In a hypothetical population of solid and non‐enhancing Grade II‐IV gliomas, the prevalence of LGGs and HGGs is 72% and 28%, respectively. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Given 100 patients with solid and non‐enhancing infiltrative gliomas, 72 will have LGG and 28 with HGG. </p> <p>Of 72 patients with LGG, it is expected 12 patients will be misclassified to have HGG (but this could potentially be between 5 to 24 patients) and may undergo surgery, thus risking early neurologic deterioration. Meanwhile, of 28 patients with HGG, 15 will be misclassified to have LGG (but this could be between 3 to 25 patients), which may lead to a delay in treatment that can potentially adversely affect outcomes. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generally low risk of bias in the patient selection domain, excepting 2 out of 7 studies with unclear patient sampling and inappropriate exclusion of small tumours. </p> <p>High risk of bias in the index test domain, mainly because 6 out of 7 studies did not use a pre‐specified threshold. However this did not affect meta‐analysis as we used a common rCBV threshold of 1.75.<br/> Generally low risk of bias in the reference standard domain, excepting 2 out of 7 studies with unclear method of histologic confirmation and/or presence of blinding.<br/> Low risk of bias in the flow and timing domain. </p> <p>Low concerns of applicability for the patient selection, index test and reference standard domains by using patient‐level data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low numbers (4 to 48) with target and alternative conditions per study and only 2 studies had &gt;20 patients. </p> <p>In general, individual studies had heterogeneous sensitivity and specificity, both with wide confidence intervals. </p> <p>Only 1 study had low risk of bias and low concern of applicability across all domains.</p> <p>Five studies were considered good quality (i.e., with low risk of bias in the domains of reference standard and flow &amp; timing). Their sensitivity analysis yielded sensitivity 0.80 (95% CI 0.61 to 0.91) and specificity 0.67 (95% CI 0.07 to 0.98). </p> <p>Subgroup analysis showed sensitivity/specificity of [0.92 (95% CI 0.55 to 0.99)/ 0.42 (95% CI 0.02 to 0.95) in astrocytomas and 0.77 (95% CI 0.46 to 0.93)/0.53 (95% CI 0.14 to 0.88) in oligodendrogliomas + oligoastrocytomas. </p> <p>Data were too sparse to investigate any differences across subgroups.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>HGG:</b> high‐grade glioma, <b>LGG:</b> low‐grade glioma, <b>rCBV:</b> relative cerebral blood volume </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Summary of findings table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011551-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">World Health Organization (WHO) Grading of Brain Tumors*</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WHO Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tumour histology</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pilocytic astrocytoma</p> <p>Subependymal giant cell astrocytoma</p> <p>Pleomorphic xanthoastrocytoma</p> <p>Ganglioglioma</p> <p>Ependymoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diffuse astrocytoma</p> <p>Oligodendroglioma</p> <p>Oligoastrocytoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaplastic astrocytoma</p> <p>Anaplastic oligodendroglioma</p> <p>Anaplastic oligoastrocytoma</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glioblastoma multiforme</p> <p>Gliomatosis cerebri</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>* Partial listing and specific to the tumour histology types relevant to this review.</p> <p>**These tumours are included in this table for reference only and are not part of the review. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">World Health Organization (WHO) Grading of Brain Tumors*</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011551-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">rCBV per tumour grade and per tumour histology</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Included studies</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LGG</p> <p>(Grade II)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HGG</p> <p>(Grade III+IV)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OG</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AOA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AOG</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 ± 0.95</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18 + 0.8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 ± 0.76</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 ± 1.13</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22 ± 0.57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 ± 0.53</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 ± 0.98</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0002" title="FalkA , FahlströmM , RostrupE , BerntssonS , ZetterlingM , MorellA , et al. Discrimination between glioma grades II and III in suspected low‐grade gliomas using dynamic contrast‐enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach. Neuroradiology2014;56:1031‐8. [DOI: 10.1007/s00234‐014‐1426‐z] ">Falk 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 + 0.48</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 + 0.93</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 + 0.69</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 + 0.21</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 + 0.32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22 + 1.18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0003" title="Guzmán de VilloriaJA , Mateos‐PérezJ , Fernández‐GarcÍaP , CastroE , DescoM . Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging2014;14(35):1‐10. [DOI: 10.1186/s40644‐014‐0035‐8] ">Guzman de Villoria 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07 + 0.79</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 + 0.29</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24 ±1.33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 + 0.04</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8 + 0.6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>[0.77]</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>[0.41]</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0005" title="KudoK , UwanoI , HiraiT , MurakamiR , NakamuraH , FujimaN , et al. Comparison of different post‐processing algorithms for dynamic susceptibility contrast perfusion imaging of cerebral gliomas. Magnetic Resonance in Medical Sciences : MRMS2016 [Epub ahead of print];16(2):129‐36. [DOI: 10.2463/mrms.mp.2016‐0036] ">Kudo 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 ± 1.19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.83 ± 2.34</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.31 ±1.23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.88 ±.46</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 + 2.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0006" title="MaiaACM , MalheirosSMF , DaRochaAJ , StávaleJN , GuimaraesIF , BorgesLRR , et al. Stereotactic biopsy guidance in adults with supratentorial nonenhancing gliomas: role of perfusion‐weighted magnetic resonance imaging. Journal of Neurosurgery2004;101:970‐6. [DOI: 10.3171/jns.2004.101.6.0970] ">Maia 2004</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.16 ± 0.63</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2 ± 0.35</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.9 ±.43</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.98 ± 0.57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.24 ± 0.37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.99</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011551-bbs2-0007" title="YangD , KorogiY , SugaharaT , KitajimaM , ShigematsuY , LiangL , et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical‐shift imaging protonMR spectroscopy, echoplanar perfusionand diffusion‐weighted MRI. Neuroradiology2002;44:656‐66. [DOI: 10.1007/s00234‐002‐0816‐9] ">Yang 2002</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 ± 0.17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 ± 0.08</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.29 ± 0.17</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.81</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>LGG:</b> Low‐grade glioma, <b>HGG:</b> high‐grade glioma, <b>DA:</b> diffuse astrocytoma, <b>OA:</b> oligoastrocytoma, <b>OG:</b> oligodendroglioma, <b>AA:</b> anaplastic astrocytoma, <b>AOA:</b> Anaplastic oligoastrocytoma, <b>AOG:</b> anaplastic oligodendroglioma. </p> <p>Nearly all HGGs are Grade III, except for one case of Grade IV/glioblastoma from <a href="./references#CD011551-bbs2-0001" title="CuccariniV , ErbettaA , FarinottiM , CuppiniL , GhielmettiF , PolloB , et al. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. Journal of Neuro‐oncology2016;126:279‐88. [DOI: 10.1007/s11060‐015‐1960‐5] ">Cuccarini 2016</a>, with rCBV of 0.3. Bracketed values in <a href="./references#CD011551-bbs2-0004" title="KoobM , GirardN , GhattasB , FellahS , Confort‐GounyS , Figarella‐BrangerD , et al. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types. Journal of Neuro‐oncology2016;127:345‐53. [DOI: 10.1007/s11060‐015‐2042‐4] ">Koob 2016</a> are included for completion but represent unspecified gliomas, with no reported histology. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">rCBV per tumour grade and per tumour histology</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/full#CD011551-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011551-tbl-0004"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 rCBV ‐ Law Threshold <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011551.pub2/references#CD011551-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011551.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011551-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011551-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD011551-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011551-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011551\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011551\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011551\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011551\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011551\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011551.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011551.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011551.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011551.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011551.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724798302"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011551.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724798306"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011551.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6b946d51f4ca',t:'MTc0MDcyNDc5OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 